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LEUKOTRIENE B4 LEVELS DETERMINE STAPHYLOCOCCUS AUREUS SKIN 
INFECTION OUTCOME 
 
 Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of 
severe skin infections and due to antibiotic resistance there is an intrinsic need to 
develop new immunotherapeutic strategies. Skin immune responses to infections 
require the cross-talk between phagocytes and structural cells that involves the 
secretion of cytokines, chemokines, and lipids. Leukotriene B4 (LTB4) is a 
pleiotropic lipid mediator known as a chemoattractant, but is also necessary to 
promote antimicrobial activity through B leukotriene receptor 1 (BLT1) signaling. 
However, chronic LTB4 production is associated with inflammatory diseases, 
including diabetes. People with diabetes are more susceptible to infections. The 
determinants by which LTB4/BLT1 promotes protective or detrimental immune 
responses in homeostasis and diabetes are unknown. We hypothesize that LTB4 
levels determine infection outcome; while LTB4 is necessary for infection control, 
excessive LTB4 levels promote overwhelming inflammation that impairs host 
defense. Our data show that skin macrophages were necessary for LTB4 
production and that LTB4 was vital for neutrophil direction, abscess formation, IL-
1β production, and MRSA clearance through reactive oxygen species production. 
Importantly, topical LTB4 ointment treatment enhances neutrophil direction, 
abscess formation, and bacterial clearance. Conversely, in the setting of 
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diabetes, skin macrophages drove excessive LTB4 production that promoted 
overwhelming inflammation, uncontrolled neutrophil recruitment, poor abscess 
formation, and lack of bacterial control. Diabetic mice treated with a topical 
ointment to inhibit BLT1 dampened inflammation and restored host defense by 
improving abscess formation, bacterial clearance, and overall inflammatory 
responses in the skin. These data demonstrate the balance of LTB4-induced 
inflammation is critical for regulating optimal immune responses during infections. 
This work highlights the importance of investigating the role of inflammatory 
mediators in the settings of health and disease. Targeting LTB4/BLT1 has 
therapeutic potential to regulate inflammation during MRSA skin infection by 
enhancing immune responses in settings of vulnerability or decrease 
inflammation in diabetes.  
 
C. Henrique Serezani, Ph.D., Co-Chair 
Janice S. Blum, Ph.D., Co-Chair 
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INTRODUCTION 
Immune system 
The immune system encompasses numerous cell types with specialized 
functions that work together to recognize and respond to microorganisms, self-
antigens, and environmental stimuli. These cell types are broadly categorized 
into the innate or adaptive immune system.  
The innate immune system functions as a first line of defense and the 
cells are the first responders to infection or injury [1]. Skin and mucous 
membranes serve as mechanical barriers and also produce antimicrobial 
molecules that prevent harmful microorganisms from colonizing these tissues. 
During injury or infection, the cells in the tissues (such as keratinocytes, 
fibroblasts, endothelial cells, and epithelial cells) produce inflammatory 
mediators. Additionally, hematopoietic innate immune cells (such as monocytes, 
macrophages, neutrophils, dendritic cells, and NK cells) also produce 
inflammatory mediators that contribute to inflammation. These cell types function 
together to quickly eliminate invading pathogens or damaged cells. The various 
inflammatory mediators and effector functions of innate immune cells are 
discussed in more detail in the following sections.  
It was traditionally considered that innate immune responses were generic 
to the class of pathogen and do not develop immunological memory. However, 
more recently, the concept of innate cell memory, also referred as trained 
immunity, is becoming more appreciated [2]. Innate immune cells, such as 
macrophages can be primed with a pathogen to induce metabolic reprogramming 
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or epigenetic changes that can alter their activation to a subsequent infection [3, 
4]. Macrophages and dendritic cells are professional antigen presenting cells 
meaning they process and present antigens on major histocompatibility 
complexes (MHC) to T cells, which can activate the cells.  
The adaptive immune system provides protective immunity. Cells of the 
adaptive immune system include B cells and T cells. Initial adaptive responses 
take longer to be activated compared to innate immune responses due to the 
activation, proliferation, and affinity maturation steps [5]. B cells are professional 
antigen presenting cells and produce antibodies. Antibodies can neutralize 
antigens and also enhance phagocytosis of pathogens by macrophages through 
opsonization. There are two major types of T cells, CD8 cytotoxic T cells and 
CD4 helper T cells. Cytotoxic T cells are able to directly kill cells, which is 
important for eliminating infected cells and tumor cells. There are multiple 
classes of helper T cells, which produce various cytokines that modulate immune 
responses, such as T regulatory cells that suppress activation and Th1 cells that 
aid in activating macrophages [6, 7].  
There is great importance for the immune system to recognize self from 
non-self. Recognition of self-antigens contributes to autoimmune diseases, such 
as type 1 diabetes. Additionally, the activation of these cells and the balance of 
inflammatory mediators are important for promoting beneficial immune 
responses. Impaired activation contributes to unregulated inflammation and poor 
host defense to infections [8-10]. 
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heat, and redness [11, 12]. These responses result in increased blood flow and 
fluid accumulation, causing swelling. Chemokines (such as CXCL1, CXCL2, and 
CCL2) recruit neutrophils, monocytes, and other cells to the site of injection/injury 
[13]. The severity and location of inflammation could result in loss of function 
such as in instances of extreme swelling or pain. Inflammation is resolved when 
infection and debris are removed, swelling and redness are eliminated, and 
tissue remodeling occurs [14].  
Inflammation is necessary for regulating physiological homeostasis and 
promoting immune responses to eliminate invading pathogens and removing 
damaged cells [15]. Once infection or injury is eliminated, homeostasis is 
returned. However, certain circumstances alter or delay the onset of inflammation 
or resolution. These circumstances can result in immunosuppression or chronic 
inflammation. Infections that fail to be cleared can lead to poor wound healing, 
autoimmune diseases, and hypersensitivity which are all associated with poorly 
controlled inflammation [16]. Unbalanced or unregulated inflammation impairs 
host activation, which can increase susceptibility to infections such as with 
malnutrition-induced immunosuppression [17] or obesity-induced chronic 
inflammation [10]. The balance of inflammatory mediators is critical for 
maintaining homeostasis and for responding to infections. 
 
Innate immunity and phagocytes 
Some innate immune system cells are phagocytes: monocytes, 
macrophages, neutrophils, and dendritic cells. Although many other cells also 
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participate in innate immune responses, the research goals for this work focus on 
the roles of macrophages and neutrophils.  
Monocytes are immune cells that arise from common-myeloid progenitors 
from the bone marrow. Monocytes migrate to tissues and differentiate into the 
tissue-resident macrophages [18]. Macrophages can also arise from the yolk sac 
or fetal liver and many tissue-specific macrophages proliferate locally to replenish 
populations in situ [19]. Macrophages reside within tissues and develop 
specialized functions depending on the tissue-environment. Macrophages exhibit 
plasticity, meaning that their functions can change depending on 
microenvironment and activation [20]. It was thought that macrophages are either 
classically-activated (M1) or alternatively-activated (M2), which promote pro-
inflammatory or anti-inflammatory processes, respectively [21]. However, it is 
more recently appreciated that macrophages have many more functions, which is 
better represented as a spectrum of macrophage activation and function [22]. At 
the site of injury or infection, tissue-resident macrophages produce signals, such 
as chemokines and lipid mediators, to induce the recruitment and activation of 
other cell types that participate in the inflammatory process. Macrophages are 
phagocytic cells, meaning that they “eat” or engulf pathogens. Along with 
pathogens, macrophages are also able to engulf apoptotic cells, a process 
known as efferocytosis. Macrophages also have anti-inflammatory or resolution 
functions, which serve to dampen pro-inflammatory signaling and to promote 
wound healing and tissue repair. 
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Neutrophils, like monocytes/macrophages, also arise from common 
myeloid progenitor cells. Neutrophils are the most abundant type of white blood 
cell in circulation in human blood, comprising 40-60% of leukocytes [23]. In mice, 
neutrophils make up 10-25% of leukocytes in the blood [24]. In response to 
infection or injury, neutrophils are typically the first cells to be recruited to the 
area where they can exert their effector functions. Similar to macrophages, 
neutrophils are phagocytic cells that can engulf pathogens. Unlike macrophages, 
neutrophils are granulocytes and contain various types of granules [25]. These 
granules contain antimicrobial molecules and enzymes and that function to 
destroy pathogens and degrade extracellular matrix (ECM) molecules [26]. Inside 
neutrophils, granules fuse with the phagosome to aid in intracellular pathogen 
killing. Also, granule contents can be released from the cell in a process known 
as neutrophil degranulation. Neutrophils also produce neutrophil-extracellular 
traps (NETs), which are DNA and proteases released from the cells that aid in 
trapping pathogens [27]. Macrophages are also capable of producing 
extracellular traps, termed METs [28], however these are less characterized than 
NETs.  
 
Leukotriene synthesis 
 Leukotrienes (LTs) are part of the large family of lipids termed 
eicosanoids, which also include prostaglandins and hydroxyeicosatetraenoic 
acids (HETEs). Eicosanoids are polyunsaturated fatty acids composed of twenty 
carbons, aptly named from the Greek word “eicosa” meaning twenty. These lipids 
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α and MMP production [48]. 12-HHT has been shown to be important for 
keratinocyte wound healing in diabetic mice [54]. Additionally 12-HETE and BLT2 
effects have been shown to be important for enhancing VEGF expression and 
promoting wound healing [55]. Although other lipid mediators promote beneficial 
wound healing responses through BLT2 signaling, less is known about specific 
LTB4/BLT2 effects on phagocyte effector functions during infections. The 
research goals here focus on LTB4/BLT1 effects. 
 
Pattern recognition receptors and signaling  
 Innate immune cells use pattern recognition receptors (PRRs) to detect 
pathogen-associated and danger-associated molecular patterns (PAMPs and 
DAMPs, respectively). The functions of PRRs include stimulating phagocytosis, 
inducing production of cytokines and other inflammatory mediators, and 
facilitating chemotaxis [56]. 
 Toll-like receptors (TLRs) are known to detect both PAMPs and DAMPs. 
There are 11 TLRs in human and 13 in mouse. TLRs can be found on the cell 
surface or located within endosomes in the cytoplasm and are activated by 
different agonists [57]. TLR1/2 and TLR2/6 on the cell surface recognize 
lipopeptides that are found on gram-positive bacteria [58]. TLR activation is 
dependent on different adaptors such as myeloid differentiation factor 88 
(MyD88) and TIR-domain-containing adapter-inducing interferon-β (TRIF). Most 
TLRs, except TLR3, utilize MyD88. Only TLR3 and TLR4 utilize TRIF. MyD88 
activation is followed by phosphorylation of downstream molecules such as 
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IRAKs and TAK-1. Signaling cascades activate transcription factors to promote 
gene expression. Activation of nuclear factor kappa B (NFκB) induces 
transcription of pro-inflammatory cytokines such as TNF-α and IL-1β [59].  
LTB4 is involved in TLR activation [60-62]. TLR signaling induces pro-
inflammatory cytokine responses [57, 63]. LTB4 stimulation upregulates the 
expression of TLR2 (cell surface receptor that recognizes peptidoglycan 
molecules) and TLR9 (endosomal receptor that recognizes DNA) in human 
neutrophils [64]. Enhanced expression of TLRs could allow for neutrophils to 
better sense various pathogens and induce a stronger signaling cascade, which 
allows for a more potent immune response. Furthermore, LTB4 is also known to 
amplify the actions of different PRRs. LTB4 enhances MyD88 expression and 
MyD88-dependent activation of NFκB, which are able to intensify the signaling 
potential of TLRs and other PPRs [60]. The mechanisms involved in LTB4-
enhanced MyD88 expression relies on enhancing the activation of signal 
transducer and activator of transcription 1 (STAT1) [65]. BLT1 activation leads to 
mRNA degradation of suppressor of cytokine signaling 1 (SOCS1), a major 
STAT1 negative regulator, which contributes to elevated MyD88 expression and 
subsequent enhancement of TLR-mediated macrophage activation [60]. 
Furthermore, it has been shown that LTB4 amplifies the phosphorylation of IRAK 
and TAK-1 in human neutrophils [62]. Through TLR and PRR activation, LTB4 
amplifies the induction of cytokine production. LTB4 is known to induce cytokines 
and chemokines that have roles in inflammatory responses: GM-CSF, TNF-α, IL-
6, IL-1β, CXCL1, MCP-1, and CXCL2 [66, 67].  
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Migration and chemotaxis  
 The production of chemokines and lipid mediators after infection or injury 
induce the migration of cells to the area. Neutrophils are typically the first cells to 
migrate to the site, followed by monocytes. Neutrophil recruitment from the 
bloodstream to the site of infection or injury involves a series of events: rolling, 
chemokine-activation, firm adhesion, and transendothelial migration [68]. 
Neutrophil rolling involves weak interactions between P-selectin glycoprotein-1 
(PSGL-1) and P-selectin on endothelial cells [69]. Chemokine activation induces 
stronger neutrophil adhesion through activating integrins including intercellular 
adhesion molecule 1 (ICAM-1) [70]. Neutrophil transendothelial migration occurs 
when the cells migrate through the tight junctions between endothelial cells and 
follow chemoattractant gradients.  
Once cells migrated to the site of infection or injury, cells must then be 
directed towards a location. Chemotaxis is the migration of a cell towards a 
molecular signal. These signals include chemokines, lipid mediators, 
complement factors, and bacterial peptides. Two major classes of chemokines 
include the CC (e.g. CCL2 – MCP-1, CCL3- MIP-1α, and CCL5 – RANTES) and 
the CXC (e.g. CXCL1 – KC and CXCL2 – MIP2α) families. CC chemokines bind 
to CCR (e.g. CCR2 and CCR7) and CXC chemokines bind to CXCR (e.g. 
CXCR1 and CXCR2) receptors. Lipid mediators, including leukotriene B4 (LTB4) 
and platelet-activating factor (PAF) are chemotactic molecules for leukocytes. 
Complement factor C5a and bacterial products N-formylmethionine-leucyl-
phenylalanine (fMLP) activate innate immune cells and are end-target 
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chemotactic molecules. Since there are many molecules that are chemotactic for 
cells, there is a hierarchy of signals that allow cells to prioritize end-target 
chemoattractants over intermediate signals, such as CXC chemokines and LTB4 
[71].  
LTB4 is well known for its role as a neutrophil chemoattractant from distant 
sites to the site of inflammation [72-74]. LTB4 is also chemotactic for other cells 
such as cytotoxic CD8 effector T cells [75], dendritic cells [76], and monocytes 
[77]. Also, LTB4 participates with chemokine gradients to further enhance 
neutrophil chemotaxis towards other chemoattractants such as fMLP, C5a, and 
heme [78-80], aiding to guide cells to end-target signals and promote neutrophil 
accumulation. Directed neutrophil accumulation and clustering is termed 
swarming. Ltb4r1-/- neutrophils have smaller neutrophil clusters than wild type 
(WT) neutrophils [81], demonstrating the importance of LTB4/BLT1 signaling in 
neutrophil accumulation. Additionally, neutrophil recruitment is not unidirectional. 
Reverse transendothelial migration has been reported where neutrophils reenter 
the blood stream after migration to the site of infection or injury [82]. In a model of 
ischemia-reperfusion injury, LTB4 and neutrophil elastase create an important 
axis that drives reverse transendothelial migration. Neutrophils that reenter the 
vasculature are able to migrate to secondary organs and have the potential to 
cause injury [83].  
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Phagocytosis 
 Phagocytosis is the engulfment of pathogens or other insoluble materials 
[84]. Phagocytosis receptors detect pathogen particles and stimulate 
phagocytosis. There are different receptors that recognize various particulates. 
C-type lectin receptor family members include dectin-1 and mannose receptor, 
which recognize sugar molecules that are cell wall components found in fungi, 
bacteria, and viruses [85]. Other phagocytic receptors include scavenger 
receptors, including MARCO which recognizes bacterial ligands [86], and CD36 
which recognizes microbial ligands as well as lipoproteins and 
phosphatidylserine (PS) found on the surface of dead cells [87]. Additionally, 
phagocytosis can be enhanced with opsonins that coat the surface of the 
pathogen, such as antibodies and complement proteins. Antibodies and 
complement proteins are recognized by Fc receptors (FcR) and complement 
receptors that stimulate phagocytosis [88].  
 Engulfment is an actin-dependent process mediated by F-actin 
polymerization [89]. The cytoskeleton of the phagocyte surrounds the particulate 
forming a phagocytic cup. Engulfed pathogens are internalized into the 
phagosome. Phagosomes are fused with lysosomes, which contain digestive 
enzymes, and form the phagolysosome [90]. The phagolysosome acidifies, which 
activates enzymes that degrade pathogens and cellular debris. These digested 
particles can be loaded and presented on MHC proteins or released from the cell 
by exocytosis [91, 92].  
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LTB4/BLT1 signaling amplifies the actions of different signaling 
components required for ingestion of particles. The first demonstration that LTB4 
enhances phagocytosis was shown by Wirth et al using a model of Trypanosoma 
cruzi infection [93]. After this, Dr. Peters-Golden’s group pioneered in 
demonstrating the role of endogenous LTs in amplifying phagocytosis of 
antibody-opsonized targets [94, 95]. Both genetic and pharmacologic blockage of 
LTB4/BLT1 actions greatly reduces ingestion of a myriad of pathogens, including 
both gram-positive bacteria (Streptococcus pneumoniae [53]), gram-negative 
bacteria (Klebsiella pneumoniae [96]), fungi (Histoplasma capsulatum [97, 98], 
Candida albicans [99], and Paracoccidioides braziliensis [100]), and parasites 
(Leishmania braziliensis [101], L. amazonensis [102], and T. cruzi [93, 103]).  
The molecular mechanisms involved in LTB4-mediated amplification of 
phagocytosis have been studied. BLT1 signaling enhances activation of Syk, a 
protein tyrosine kinase, important for FcγR-mediated phagocytosis [43, 50]. 
When macrophages are challenged with opsonized-targets, LTB4 enhances 
phagocytosis of opsonized red blood cells in an FcγR1-dependent manner. This 
enhancement is attributed to the association of BLT1 with lipid raft formation and 
heightened signaling capabilities [104]. Furthermore, LTB4 amplifies 
phagocytosis by increasing phosphorylation of kinases involved in the formation 
of a phagocytic cup, such as PKC-α, PKC-δ, PI3K, and ERK1/2 [105, 106]. 
However, the hierarchical role of these kinases in amplifying phagocytosis 
remains to be determined. It has been shown that LTB4 enhances C. albicans 
phagocytosis via activation of Gαi-mediated PKC-δ and PI3K activation resulting 
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in F-actin polymerization [107]. LT enhancement of yeast phagocytosis involves 
the activation of PKC and PI3K, with subsequent activation of LIM kinase, 
decreased cofilin-1 activation, and ultimately, F-actin polymerization [107]. 
Furthermore, LTB4 enhances phagocytosis of fungi by increasing the expression 
of dectin-1, a main phagocytic receptor detecting fungal pathogens [97]. LTB4-
mediated dectin-1 expression is dependent on GM-CSF production and 
activation of the transcription factor PU.1 [99]. 
 
Antimicrobial activity 
 Antimicrobial effector functions are necessary for destroying and killing 
pathogens. These functions include the production of antimicrobial peptides, 
reactive oxygen species (ROS), reactive nitrogen species (RNS), and 
antimicrobial activity facilitated by cytokines, such as inflammasome activation 
and IL-1β production.  
 Antimicrobial peptides include cathelicidins, LL37 found in human and the 
mouse homolog cathelicidin-related antimicrobial peptides (CRAMP), and 
defensins. These peptides interact and disrupt bacterial membranes. Neutrophils 
kill pathogens by producing toxic components within granules that are released in 
a process known as neutrophil degranulation [108]. When human neutrophils are 
infected in vitro with the parasite L. amazonensis, endogenous and exogenous 
LTB4 promotes neutrophil degranulation [102]. Also, LTB4 induces release of 
myeloperoxidase [109] and elastase in neutrophils [83, 110]. LTB4 treatment in 
mice infected with influenza virus induced production of antimicrobial peptides 
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including β-defensins and CRAMP [111]. In human neutrophils, LTB4 induces the 
production of LL37 in a dose-dependent manner [112]. 
ROS species include superoxide and hydrogen peroxide. The major 
source of ROS in phagocytes is through nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase activity. NADPH oxidase is composed of several 
subunits: gp91phox and gp22phox are membrane bound subunits and gp47phox, 
p40phox and p67phox are cytosolic subunits. Once activated, the cytoplasmic 
subunits and Rac GTPase translocate and associate with the membrane bound 
subunits. NADPH activity generates superoxide (O2-). NADPH oxidase is an 
important complex and the functions are necessary for eliminating infections. 
Defects in these enzymes or activity greatly increase susceptibility to infections. 
People with the genetic disease chronic granulomatous disease (CGD) have 
defective NADPH oxidase functions, which prevent the ability to effectively 
eliminate infections. LTB4 enhances the production of NADPH oxidase-
dependent ROS generation in phagocytes [113, 114]. LTB4 enhances NADPH 
oxidase activation via phosphorylation of the cytosolic subunit p47phox that is 
dependent on PKC-δ [114], ERK-1/2 and PI3K activation [115]. LTB4 is part of a 
positive-feedback loop in human neutrophils infected with L. amazonensis, which 
is important to kill parasites [102]. LTB4-mediated ROS production in 
macrophages is dependent on PKC-δ-mediated p47phox and p40phox 
phosphorylation and membrane translocation in alveolar macrophages 
challenged with opsonized K. pneumonia [106]. Furthermore, aerosolized LTB4 
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increases p47phox expression and membrane translocation during Streptococcus 
pneumoniae lung infection [116]. 
Nitric oxide (NO) is a major reactive nitrogen species (RNS) and is 
produced from nitric oxide synthase. NO has various functions that include 
antimicrobial activity and anti-tumor activity [117]. NO induces smooth muscle 
cells to contract, resulting in vasodilation. Additionally, NO is also involved in 
regulating cytokine production and immune cell activation. LTB4-dependent RNS 
production is dependent on NFκB and STAT1 activation [101]. LTB4 treatment 
further enhances the production of NO in murine macrophages, which improves 
killing of different pathogens such as L. amazonensis and T. cruzi [106, 118].  
Other antimicrobial activity functions are a result of cytokine production, 
such as IL-1β. IL-1β is produced as an inactive pro-IL-1β, which requires 
maturation to be functional. The NLRP3 inflammasome is a major mechanism 
that processes IL-1β and facilitates antimicrobial activities and enhances immune 
effector functions [119]. In a model of monosodium urate (MSU)-induced gout, 
LTB4 was shown to mediate inflammasome activation [120]. NLRP3 
inflammasomes are multi-subunit protein complexes involving NLRP3, ASC, and 
caspase-1. Once assembled, caspase-1 is activated and cleaves pro-IL-1β to 
form mature IL-1β. Effective IL-1β processing by NLRP3 requires two signals: 1) 
TLR activation to induce expression of Il1b and 2) activation signal to induce 
inflammation assembly and activity. Alternatively, IL-1β can also be processed in 
noncanonical NLRP3 activation, mediated through caspase-11 activation. Also, 
IL-1β can be processed via inflammasome-independent mechanisms by serine 
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proteases from neutrophils and bacterial proteases [121]. The majority of IL-1β 
produced in the skin of S. aureus infected mice is processed primarily through 
NLRP3 inflammasome activity as opposed to non-canonical inflammasome 
activation or inflammasome-independent processes [122]. 
 
Methicillin-resistant Staphylococcus aureus 
 Staphylococcus aureus is a gram-positive bacterium and is commonly 
found as part of normal human skin microbiota in ~30-50% of the population. 
Often referred as an opportunistic pathogen, S. aureus colonization can occur 
asymptomatically. However, if presented an opportunity, such as through a break 
in the skin, inhalation, or ingestion, S. aureus can cause symptomatic infections. 
 Antibiotic resistant strains have emerged which pose a challenge to 
effectively treat infections caused by these pathogens. A notable example is 
methicillin-resistant S. aureus (MRSA). MRSA infections were traditionally limited 
to hospital settings but community-acquired MRSA (CA-MRSA) strains emerged 
[123]. In addition to antibiotic resistance, some CA-MRSA strains such as 
USA300 produce more potent virulence factors, which enable these strains to 
cause infections in otherwise healthy individuals [124-126]. These virulence 
factors can induce tissue damage, which can cause more severe infections [125]. 
Infections with MRSA strains, especially in immunocompromised hosts, pose a 
serious public health risk. 
The development of other strategies to treat antibiotic-resistant infectious 
diseases is greatly needed. One strategy includes immunomodulatory therapies, 
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which enhance or suppress immune responses leading to improved host defense 
mechanisms [127]. The mediators involved during inflammation may provide a 
target for immunomodulatory therapies to promote or restrain immune activation 
in various settings of infectious diseases or chronic inflammatory diseases. 
 
Skin biology and immune response to S. aureus 
 The skin is composed of the epidermis and the dermis, and serves as an 
immune barrier preventing pathogen entry. Keratinocytes form the outer layer of 
the epidermis. The inner layer of the skin, the dermis, contains extracellular 
matrix proteins (ECM), blood vessels, subcutaneous adipose tissue, fibroblasts, 
and tissue-resident immune cells including macrophages.  
Keratinocytes produce antimicrobial peptides, which provide a chemical 
barrier to pathogens. The epidermis also serves as a mechanical barrier 
preventing entry of harmful pathogens. During infection, the tissue-resident cells 
along with keratinocytes produce cytokines, chemokines, and lipids, which aid in 
the recruitment of immune cells to the site of infection. Neutrophils are recruited 
in to the site and promote the development of an abscess. Abscesses develop in 
stages: cell death surrounded by live neutrophils, all encapsulated with a fibrous 
material [128].  
Cell death is another common characteristic of S. aureus skin infections. 
MRSA produces toxins, such as panton-valentine leukocidin (PVL) that is a pore 
forming toxin that induces necrosis and apoptosis [124]. The dead cells and other 
debris require clearance by phagocytes, which is a processed called 
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efferocytosis. The removal of apoptotic cells by macrophages typically does not 
activate immune responses. However, if apoptotic cells are not cleared properly, 
they can become necrotic and secrete DAMPs, further stimulating inflammation. 
Ingestion of necrotic cells by macrophages can activate different cell functions 
compared to ingestion of apoptotic cells. Necrotic-neutrophil uptake by 
macrophages enhances MHC presentation and T cell activation, which does not 
occur with apoptotic-cell ingestion [129]. After infection and debris are eliminated, 
fibroblasts and macrophages produce molecules to aid in the ECM remodeling.  
 
Aberrant LTB4 and poor host defense  
Chronic inflammatory morbidities are accompanied by aberrant LTB4 
production and high production of inflammatory cytokines. Diseases in which 
LTB4 plays a detrimental role include type-1 and type-2 diabetes, arthritis, and 
atherosclerosis [130-136]. LTB4 has beneficial roles in promoting antimicrobial 
effector functions in phagocytes, but the bad reputation of LTB4 comes from its 
capacity to maintain inflammatory programs in monocytes and macrophages and 
prolonging neutrophil recruitment to the inflammatory foci. LTB4/BLT1 blockade is 
expected to dampen inflammatory responses and restore tissue homeostasis 
during chronic inflammation.  
Besides increased production of LTB4, chronic inflammatory diseases are 
often associated with co-morbidities, including the major threat of increased 
susceptibility to infections. Although LTB4 plays a beneficial role in promoting 
pathogen clearance, the counterintuitive effect of LTB4 in chronic inflammatory 
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diseases could be explained by the overwhelming inflammatory response and 
lack of proper phagocyte response to pathogens. Abundant LTB4 production and 
detrimental host defense responses have been associated in a zebrafish model 
of Mycobacterium marinum infection. The authors showed that LTA4 hydrolase 
(LTA4H), the enzyme that converts LTA4 to LTB4, is an important susceptibility 
factor involved in Mycobacterium infection. Zebrafish expressing hyperactive 
LTA4H are hypersusceptible to M. marinum infection [137]. Additionally, 
overexpression of LTA4H produces high levels of LTB4 that drive aberrant TNF-α 
production and uncontrolled mycobacterial infections [138]. Furthermore, 
zebrafish expressing the enzyme that inactivates LTB4, leukotriene B4 
dehydrogenase/prostaglandin reductase 1 (LTB4DH/PTGR1), exhibit lower 
bacterial numbers than WT zebrafish. The susceptibility to infection of LTB4DH 
mutant animals can be reversed with BLT1 antagonism, further implicating LTB4 
as detrimental to host defense during Mycobacteria infection in zebrafish [139].  
Exaggerated LTB4 is also detrimental to systemic infection such as sepsis. 
Alox5-/- mice or pharmacological inhibition of BLT1 protect mice during cecum 
ligation and puncture (CLP). Alox5-/- mice and WT mice treated with a LT 
synthesis inhibitor, AA861, have drastically lower levels of neutrophil infiltrates 
and lower levels of inflammatory cytokines such as IL-1β in the peritoneal cavity 
[140]. During CLP-induced sepsis, treatment with the BLT1 antagonist U-75302 
decreases lung injury [141] as evidenced by decreased neutrophil recruitment. 
Therapeutically regulating 5-LO products or blocking BLT1 during or after sepsis 
may help prevent organ injury.  
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Diabetes 
 Diabetes represents a family of diseases characterized by an inability to 
produce insulin or reduced sensitivity to insulin signaling. Insulin is a hormone 
produced from pancreatic β cells that aids in regulating blood glucose levels. 
Insulin signaling through the insulin receptor induces muscle and adipocytes to 
express glucose transporters on the cell surface, which in turn induces the 
uptake of glucose by these cells thereby reducing blood glucose levels. 
There are two major types of diabetes, Type 1 (T1D) and Type 2 (T2D). 
T1D is an autoimmune disease in which the insulin-producing pancreatic β cells 
are targeted for destruction. T1D is associated with the development of 
autoreactive T cells and production of autoreactive antibodies. People with T1D 
are typically diagnosed in adolescence. The lack of insulin requires T1D patients 
to take recombinant insulin to help regulate blood glucose levels. The exact 
cause of T1D is not well understood. There is likely a genetic component but 
other factors such as viral infection or other environmental factors may also be 
involved [142]. People with T2D are typically in adulthood when diagnosed and 
the disorder is often associated with obesity. T2D is caused by insulin resistance, 
in which insulin receptor signaling is no longer effective at regulating blood 
glucose levels. Pancreatic β cells produce more insulin to compensate for the 
insulin resistant tissues. However, β cells can become fatigued and fail to 
produce insulin. Treatments for people with T2D include medication to improve 
insulin receptor sensitivity or to reduce blood glucose levels.  
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Diabetes and infection risk 
 Uncontrolled hyperglycemia is often associated with numerous co-
morbidities such as neuropathy, kidney disease, eye disease, and risk for 
infections. People with diabetes, including both T1D and T2D, are more 
susceptible to developing infections that affect the lung, urinary tract infections, 
and skin and soft tissue infections [143, 144]. Diabetic foot ulcers that fail to heal 
often require amputation [145]. Infections and wounds inflicting skin and soft 
tissues take significantly longer to heal, and have the risk of developing 
polymicrobial infections. There is an additional risk of infections disseminating to 
other organs that can cause life-threatening infections such as sepsis, 
osteomyelitis, and endocarditis.  
 Phagocytes from people with diabetes are reported to have impaired 
function. Poor respiratory burst and defective phagocytosis are associated with 
poor bacterial clearance. Immune cells from mice and rats with diabetes are 
reported to have poor phagocytosis and cytokine production [146-148]. Others 
suggest that neutrophils in people with diabetes have poor recruitment to the site 
of infection or injury, contributing to the susceptibility to infections [149].  
 Since people with diabetes are more susceptible to infections, an initial 
hypothesis would be that people with diabetes produce lower levels of 
inflammatory mediators, which promote host defense. However, many of these 
mediators, such as LTB4, promote host defense mechanisms by boosting 
inflammation. Since diabetes is associated with chronic low-grade inflammation, 
the levels of inflammatory mediators are altered even in the absence of infection. 
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The role of these inflammatory mediators in infections complicated with diabetes 
is unknown. Along with other inflammatory mediators, LTB4 levels are higher in 
the serum of mice and people with diabetes [150]. A better understanding on how 
diabetes alters immune functions could allow for the development of new 
therapies to restore host defense in this vulnerable population to prevent 
infection risk and severity. 
 
Research goals 
The ability to regulate inflammation is critical for maintaining homeostasis 
and promoting effective immune responses during infection. However, chronic 
inflammatory diseases alter the homeostatic levels of these mediators that 
contribute to low-grade inflammation, including elevated LTB4 levels. Diabetes is 
a chronic inflammatory disease and is a risk factor for comorbidities including 
enhanced susceptibility to infections. The hypothesis for this work is that the 
threshold of LTB4 production determines the outcome of MRSA skin infection. 
This hypothesis was tested by investigating the role of LTB4 during MRSA skin 
infection under both homeostasis and diabetes-like conditions.  
 Due to the immunostimulatory effects of LTB4, one research goal was to 
evaluate its role in orchestrating the immune response to MRSA skin infection in 
wild type (WT) C57BL/6 mice. For this goal, the aims were to: 1) determine 
whether endogenously produced LTB4 promotes host defense mechanisms, 2) 
determine the role of skin resident macrophages in MRSA skin infection, and 3) 
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evaluate the effectiveness of topical LTB4 application as use as an 
immunotherapeutic strategy for treating MRSA skin infection.  
The second research goal was to evaluate the role of LTB4 in MRSA skin 
infections in mice with a disease model that exhibit exaggerated LTB4 levels, 
such as diabetes. The aims in this goal were to: 1) determine how excessive 
LTB4 levels in the skin drive overwhelming inflammation in diabetic mice, 2) 
determine the role of tissue macrophages on LTB4 production during MRSA skin 
infection, and 3) evaluate the therapeutic potential of blocking BLT1 actions in 
diabetic mice during MRSA skin infection.  
This work highlights the importance of studying inflammation and the 
mediators that regulate immune responses. Targeting LTB4/BLT1 has 
therapeutic potential for enhancing or dampening inflammation as necessary. 
This suggests that people who are immunocompromised may benefit from 
exogenous LTB4 treatment. Conversely, people with chronic inflammatory 
diseases may benefit from BLT1 antagonist treatment. This treatment strategy 
may help restore host defense mechanisms during infections. 
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MATERIALS AND METHODS 
Mice 
 Mice were purchased through Jackson Mice or were donated from other 
investigators. LysEGFP mice were a gift from Dr. Nadia Carlesso (City of Hope, 
Duarte, CA) and pIL1DsRED mice were a gift from Dr. Akiko Takashima 
(University of Toledo, Toledo, OH). Colonies of mice were bred and maintained 
at Indiana University School of Medicine in Indianapolis, IN or Vanderbilt 
Strain  Information Reference 
C57BL/6 Wild type (WT) mice   Jackson Laboratory 
Ltb4r1-/- LTB4 Receptor 1 total knockout (C57BL/6 background)  Jackson Laboratory 
Alox5-/- 5-lipoxygenase total knockout (C57BL/6 background)  Jackson Laboratory 
pIL1DsRED 
Il1beta reporter mouse 
expressing DsRED (C57BL/6 
background) 
[151] 
Cybb-/- 
Total knockout for gp91phox 
(membrane bound subunit of 
NADPH oxidase) (C57BL/6 
background) 
 Jackson Laboratory 
MMDTR 
Csf1rLLsL-DTR-mCherry crossed with 
LysMcre 
Monocyte-macrophage DTR-
mCherry (C57BL/6 background) 
Parent strains 
available at Jackson 
Laboratory 
[152] 
 
LysEGFP 
LysMEGFP  
Myeloid lineage express GFP 
(C57BL/6 background) 
 [153] 
NOD Non-obese diabetic (type 1 diabetes mouse model).   Jackson Laboratory 
Table 4. List of mouse strains. 
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University Medical Center in Nashville, TN. All experimental procedures were 
approved by the Institution Animal Care and Use Committee (IACUC) at Indiana 
University or Vanderbilt University Medical Center. Mouse strains utilized are 
listed in Table 4. 
 C57BL/6 and NOD mouse colonies were maintained by breeding brother-
sister mating pairs. Ltb4r1-/-, Alox5-/-, and Cybb-/- mouse colonies were 
maintained by breeding homozygous knockout brother-sister mating pairs to 
maintain homozygosity. 
pIL1DsRED mice are Il1b reporter mice that have a DsRED construct 
under the promoter of Il1b [151]. C57BL/6 mice were bred with pIL1DsRED 
heterozygous mouse to maintain heterozygosity, which was determined by 
genotyping for DsRED by PCR. Littermate controls lacking DsRED were used as 
non-fluorescent controls.  
Monocyte/macrophage diphtheria toxin receptor (MMDTR) mice are 
Csfr1LsL-DTR-mCherry_LysMcre [152]. Csfr1LsL-DTR-mCherry mice have a construct 
containing a floxed stop codon followed by diphtheria toxin receptor (DTR) and 
mCherry which is under the Csfr1 gene. When bred with LysMcre mice, cre 
expressed in monocytes and macrophages excise the floxed stop codon, which 
allows for expression of the DTR-mCherry fusion protein. MMDTR mice allow for 
the detection of monocytes/macrophages by mCherry fluorescence and specific 
cell ablation when mice are treated with diphtheria toxin (DT). Mice containing 
the floxed stop codon-DTR-mCherry construct but lacking cre expression were 
used as controls.  
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LysEGPF mice express enhanced green fluorescent protein (EGFP) in all 
myeloid cells [153]. Mouse colonies were maintained by breeding brother-sister 
pairs that are GFP+. Mice were monitored for GFP fluorescence by collected a 
drop of blood from tail vein puncture and analyzing cells by flow cytometry or by 
genotyping for GFP by PCR. 
 
MRSA preparation 
 The MRSA USA300 LAC strain was a gift from Dr. Bethany Moore 
(University of Michigan, Ann Arbor, MI) [154]. The bioluminescent USA300 
(NRS384 lux) strain was a gift from Dr. Roger Plaut (Food and Drug 
Administration, Silver Spring, MD) [155]. The GFP-expressing USA300 strain 
was a gift from Dr. William Nauseef (University of Iowa, Iowa City, IA) [156]. 
MRSA stocks were stored in the -80°C freezer. Frozen MRSA aliquots were 
transferred to a 50mL conical tube containing 10mL tryptic soy broth (TSB) and 
allowed to incubate overnight shaking at 200rpm at 37°C with a loose cap to 
generate a saturated culture. The following day, the saturated culture was sub-
cultured 1:100 (100µL of culture into 10mL new TSB in 50mL conical tube) and 
allowed to shake at 200rpm for 3 hours at 37°C. To determine bacterial density, 
the culture was diluted 1:10 in TSB and the OD600 was measured and compared 
to the growth chart that was previously generated for each MRSA strain (Table 
5). The growth chart was created by measuring the OD600 on 2-fold serial 
dilutions from a saturated culture of MRSA. Each sample in the 2-fold series was 
further diluted by 10-fold serial dilutions and spotted onto tryptic soy agar (TSA) 
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MRSA/mL in PBS. Bacteria preparations used for MRSA skin infections were 
serially diluted and plated onto TSA plates to determine actual infection 
inoculum.  
 In order to generate heat-killed MRSA (HK-MRSA), MRSA was pelleted, 
washed in PBS, and resuspended in 1x109 MRSA/mL. Bacteria was heat-killed 
by incubating tubes on a heating block at 60°C for 1 hour. In order to confirm 
bacterial killing, HK-MRSA was plated onto TSA plates.  
 
MRSA skin infection model 
 Murine skin infection model was adapted from [157]. Male and female 
mice between 6-12 weeks of age were used for MRSA skin infection. Fur from 
the back of mice was removed with a fur trimmer, cleansed with 70% ethanol, 
and injected with 50µL of approximately 1x108 MRSA/mL subcutaneously using a 
1mL syringe and 30G1/2 needle to aim for approximately 3x106 MRSA to infect. 
Infection areas were measured with a caliper and areas were calculated by area 
X width for mm2. Biopsies and sample collection were taken at various times 
after infection ranging from 6 hours to 9 days post infection. To collect biopsy 
samples, mice were euthanized with CO2. The exterior of the skin was cleansed 
with 70% ethanol, allowed to dry, and a 8mm-diameter biopsy punch was used to 
collect the infected area of skin (or naive skin, for uninfected controls). Biopsy 
punches were sectioned and processed for the following analyses: histology, 
RNA for qRT-PCR, cytokine for enzyme immune assay (EIA)/enzyme-linked 
immunosorbant assay (ELISA)/multiplex, bacterial burden colony forming units 
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(CFU) counts, dissociation for flow cytometry analysis, sample prep for 
eicosanoid core mass spectrometry analysis, or sample prep for MALDI analysis. 
Processing methods for these various samples are described in more detail in 
the following sections. 
 
Immunohistochemistry of skin biopsy sections 
 Histology samples were collected by 8mm biopsy bunch. Tissue was fixed 
overnight in 100µL 4% paraformaldehyde and transferred to 70% ethanol for 
storage prior to paraffin embedding. Paraffin embedding and sectioning was 
performed at the histology core at Indiana University School of Medicine or at the 
Translation Pathology Resource Core (TPSR) at Vanderbilt University. Tissue 
staining for the following stains were performed at the Vanderbilt TPSR core: 
H&E, Masson’s trichrome blue for collagen, Phosphotungstic acid-hematoxylin 
(PTAH) for fibrin and collagen, F4/80 IHC for macrophage, Ly6G/C IHC for 
neutrophil, and gram stain for bacteria. Slides were visualized and pictures 
acquired on Nikon Eclipse Ci and camera Nikon Ds-Qi2. 
 IHC for 5-LO was performed on 5µm paraffin-embedded sections by the 
following steps: 1) Deparaffinized tissue with sequential washes in xylene, 100% 
ethanol, 95% ethanol, 70% ethanol, 50% ethanol, and water. Slides were 
incubated for 2 minutes in each buffer. 2) Antigen exposure in Tris-EDTA buffer 
(10mM Tris base, 1mM EDTA, 0.05% Tween 20, pH 9.0) by submerging slides in 
the buffer in plastic slide holder. Slides were heated in a microwave for 20 
minutes. Slides were washed in Tris buffered saline (TBS) + 0.025% Triton-X. 3) 
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Slides were blocked with Vectastain blocking serum (provided in VectaLabs 
Vectastain ABC kit) for 2 hours at room temperature. 4) Blocking solution was 
removed and primary antibody to 5-LO (1:100 dilution) in TBS + 1% BSA was 
added and incubated overnight at 4°C. 5) Washed three times in wash buffer as 
described in step 2. Endogenous peroxidase activity was quenched in 0.3% 
hydrogen peroxide for 15 minutes. Slides were washed as before. 5) Using 
Vectastain ABC kit, added biotinylated antibody for slides for 1 hour at room 
temperature. Slides were washed as before. 6) Added ABC reagent to slides 
(from VectaLabs Vectastain ABC kit) and incubated for 30 minutes at room 
temperature. Slides were washed as before. 7) Developed slides with 3,3’-
diaminobenzidine (DAB) (Sigma) and reaction was stopped with water. 8) Slides 
were counterstained with hematoxylin (Sigma) for 1-5 minutes. Slides were 
rinsed in water. 9) Tissues were dehydrated in sequential washes in water, 50% 
ethanol, 70% ethanol, 95% ethanol, 100% ethanol, and xylene. Slides were 
incubated in each buffer for 2 minutes each. 10) Slides were mounted with 
Organo/limonene (Sigma) mounting medium and sealed with a glass coverslip 
and allowed to air-dry overnight. 
 Quantification of collagen thickness was performed in ImageJ. The scale 
bar was used to calibrate the measurement scale. A line was drawn over the 
edge of the collagen border surrounding the abscess and measurement taken. 
Quantification of cells in the skin were performed in ImageJ. Images were 
converted to 8-bit and adjusted the image threshold. Cells were quantified by 
analyzing particles by setting the size threshold for 10-15µm. Quantification of 
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fluorescence intensity was performed in ImageJ. An area was drawn around the 
cell and the mean area integrated intensity was measured. Background was 
determined by measuring the mean fluorescence intensity of a region next to the 
cells with no fluorescence. Background values were subtracted from the cell 
fluorescence values.  
 Immunofluorescence staining. Frozen tissue sections were blocked with 
3% BSA in PBS. Sections were labeled with 1:100 dilution of Ly6G-AlexaFluor 
594 (Biolegend) overnight at 4°C, washed with PBS + 0.005% Tween 20 for 5 
minutes for 3 washes. Tissues were mounted with ProLong Gold Antifade 
Mountant with DAPI (Thermo Fisher Scientific). Apoptotic cells were labeled with 
fluorescein isothiocyanate (FITC) by TUNEL staining kit (Millipore) following 
manufacturer’s instructions (Millipore). After staining, tissue sections were 
counterstained and mounted in ProLong Gold Antifade Mountant with DAPI 
(Thermo Fisher Scientific) and sealed with a coverglass. Slides were visualized 
and pictures acquired on Nikon Eclipse Ci with filters for DAPI, GFP, and Texas 
Red and camera Nikon Ds-Qi2. 
 
RNA isolation and gene expression analysis (qRT-PCR)  
 Skin biopsy sections for RNA isolation were homogenized in 400µL RLT 
buffer (Qiagen) + β-mercaptoethanol. Tissue was homogenized with a 
disposable pestle (Bel-Art) compatible with 1.5mL tubes. Samples were 
centrifuged at 12,000g for 10 minutes at 4°C to pellet cell debris. Supernatant 
was transferred to a new 1.5mL tube + 400µL of isopropanol. Samples were 
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FSC-A vs. FSC-H (Figure 4B). Dead cells were excluded by viability dye (Figure 
4C). Viable cells were then gated on Ly6G+ for neutrophils (Figure 4D) or F4/80+ 
for macrophages (Figure 4G). For pIL1DsRED mice, neutrophils (Figure 4E-F) 
and macrophages (Figure 4H-I) were then gated for DsRed expression to 
determine percentage of cells expressing DsRed and MFI calculated to 
determine expression of DsRed (a readout for Il1b expression).  
 
Sample preparation for mass spectrometry 
 Skin biopsy sections were collected with a 8mm-diameter biopsy punch, 
sectioned in two equal pieces and flash frozen with dry ice. Samples were 
submitted and processed at the Vanderbilt University Eicosanoid Core 
Laboratory and processed as previously described [158]. Briefly, skin samples 
were homogenized and extracted in ice-cold methanol with indomethacin and 
butylated hydroxytoluene (BHT). Samples were injected for liquid 
chromatography - mass spectrometry (LC-MS). Eicosanoids were identified and 
quantified based on the mass and amount of known standards.  
 
Sample preparation for MALDI 
 Skin biopsy sections were flash frozen with dry ice. Samples were 
submitted and processed at the Vanderbilt University Mass Spectrometry 
Research Center - Tissue Core Laboratory.  
Lipid imaging: Plates designated for lipid imaging were not washed. DHA 
was sublimed at 110°C for approximately 6 minutes at <45 torr onto the plates 
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9). Treatments were applied to cover the infected area with a clean cotton swab. 
Mice were treated once a day throughout the course of infection (ranging from 6 
hours – 9 days).  
 
IVIS in vivo imaging 
IVIS spectrum/CT (Perkin Elmer) machine was used to image 
bioluminescence or fluorescence in the mice. Mice were anesthetized with 
isoflurane and imaged while under gas anesthesia. Mice were positioned facing 
the CCD camera and imaged for the appropriate bioluminescence/fluorescence.  
Bioluminescence imaging (BLI) and analysis: The mice were scanned for 
determinant amount of time to allow for bioluminescent signal detection from 
each mouse (maximum acquisition time of 4 minutes). Mice were scanned 
longitudinal throughout the course of MRSA skin infection. A region was drawn 
around each infection and total flux (photons/second) was measured for each 
infection site. A background region was drawn to determine the background 
signal of each scan. To obtain background-free total flux signal the mouse 
infection region was subtracted from the background region. The background-
free total flux was compared to a standard curve to obtain the bacteria amount in 
each infection. The standard curve was prepared by spotting known bacterial 
CFU TSA plates (for in vitro) and infected subcutaneously in mice (for in vivo) 
and imaged. A graph of luminescence total flux on the y-axis and CFU on the x-
axis was referred to in order to quantify bacterial burden in the skin. 
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DsRed and mCherry scans and analysis: WT mice that were DsRed 
negative (or mCherry negative) served as the autofluorescence background. 
Mice were scanned using filter pairs for DsRed fluorescence or mCherry 
fluorescence. Living Image software (Perkin Elmer) was used to spectrally unmix 
the DsRed signal. A region was drawn around the spectrally unmixed DsRed 
signal (or mCherry signal) and total radiant efficiency was measured 
([photons/second]/[µW/cm2]). 
 
Two-photon intravital microscopy  
 Mice were anesthetized with a solution of ketamine/xylazine. A skin flap 
was created surrounding the infection area, adapted from [159]. Tissues were 
moistened with PBS were used to maintain moisture on the mouse. The skin flap 
was placed in a coverslip-bottomed cell culture dish for imaging and moistened 
with PBS. Temperature of mice was maintained at 36°C with two ReptiTherm 
pads. Mice were imaged for up to 1 hour. Imaging was performed using an 
Olympus FV1000-MPE confocal/multiphoton microscope. This imaging technique 
was a terminal procedure. Immediately following imaging and while still 
anesthetized, mice were euthanized by cervical dislocation. Analysis was 
performed using FIJI (Image J) tracking software using TrackMate plugin. 
 
Diabetes induction with streptozotocin 
 C57BL/6 male mice induced with 40mg/kg of streptozotocin (STZ) 
dissolved in 0.1M sodium citrate buffer [160]. Female mice were not used since 
45 
 
female mice are more resistant to developing hyperglycemia with STZ-treatment 
[161]. Mice aged 6-8 weeks were induced with the multiple low dose strategy 
(40mg/kg), one intraperitoneal injection with 0.2mL daily for 5 consecutive days. 
Nondiabetic control mice received citrate buffer as vehicle control. STZ induces 
cell death in the insulin-producing pancreatic beta cells, resulting in low insulin 
production and subsequent hyperglycemia [162]. Mice were considered diabetic 
when blood glucose levels were >250mg/dL. Mice were treated with STZ to 
induce diabetes 30 days prior MRSA skin infection. Mice were 10-12 weeks old 
at the time of MRSA skin infection. 
Both Alox5-/- and Ltb4r1-/- mice were more resistant to developing 
hyperglycemia after STZ treatments compared to C57BL/6 WT mice. These 
knockout mice were treated with 3-5 more injections of 40 mg/kg of STZ. Age-
matched WT and KO mice with similar blood glucose levels were used for 
experiments.  
 
NOD diabetes model 
 Non-obese diabetic (NOD) mice are a model for T1D. These mice 
spontaneously develop diabetes approximately 12+ weeks of age. Female NOD 
mice develop diabetes at a higher frequency than male NOD mice by week 30 of 
age (80% of females vs. 45% males). NOD breeders were maintained at Indiana 
University School of Medicine. Starting at 10 weeks of age, blood glucose levels 
were monitored weekly in female NOD mice, using OneTouch Ultra glucose 
meter and strips. When blood glucose levels reached 250mg/dL, mice were 
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considered diabetic (dbNOD). Age-matched female NOD mice that did not 
become diabetic (glucose levels ~100mg/dL but <150mg/dL) were used as 
nondiabetic NOD controls (ctNOD). Once NOD mice became diabetic, they were 
used in experiments within 1-2 weeks. Body weight was monitored and mice that 
lost more than 20% of original body weight were excluded from experimentation. 
NOD mice were approximately 12-20 weeks of age at the time of MRSA skin 
infection.  
 
Neutrophil depletion 
 Ly6G depleting antibody (clone 1A8) and IgG control (BioXcell) were 
prepared by diluting antibodies in BioXcell pH 7.0 dilution buffer. 200µg in 200µL 
of antibody was administered via intraperitoneal injection18-hours prior MRSA 
skin infection, adapted from [163]. Affected region areas were measured with 
calipers at 24 hours post infection. Skin biopsies were collected from naive 
animals, and at 6 hours and day 1 post MRSA infection and processed for 
histology as described in “Immunohistochemistry of skin biopsy sections”.  
 
Macrophage depletion 
In order to deplete macrophages, MMDTR mice were treated with 100ng 
DT or PBS vehicle control once a day for three consecutive days prior to MRSA 
skin infection (Figure 5). Biopsy punches were collected at 6 hours or 1 day post 
MRSA skin infection. Mice used for 2 day post MRSA skin infection were treated 
with 100ng DT in PBS at day 1 to continual deplete monocytes/macrophages.  
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macrophages/neutrophils to mimic low glucose (control - nondiabetic) and 4.5g/L 
glucose was used to culture cells to mimic high glucose (diabetic) conditions. 
 
Efferocytosis assay 
 Peritoneal macrophages were isolated as described in “Primary cell 
isolation” and plated in 500µL at a cell density of 1x106 cells/mL in 24-well plates 
and rested overnight. Bone marrow neutrophils were isolated as described in 
"Primary cell isolation" and labeled with CFSE (Sigma). Briefly, neutrophils were 
labeled with 2µM CFSE in PBS in 1x106 cells/mL volume for 30 minutes 
incubated at 37°C and washed with PBS. Labeled neutrophils were allowed to 
rest in DMEM for at least 30 minutes prior to experimentation. Labeled 
neutrophils were incubated with MRSA at MOI of 50:1 for 18 hours to generate 
infected apoptotic cells (IACs). IACs were confirmed apoptotic by flow cytometry 
analysis of 7AAD and AnnexinV staining. IACs were washed with PBS and given 
to macrophages at a ratio of 2 IACs per 1 macrophage. Co-cultures were 
incubated for 2 hours and cells were collected by placing plate on ice and 
scraping cells into a 5mL tube for flow cytometry activated sorting (FACS). 
Macrophages were labeled with fluorescent F4/80 antibody. Samples were 
collected on BD LSR II and analyzed using Flow Jo software. All cells were gated 
on and doublets were excluded to eliminate bound cells from the analysis. F4/80 
positive cells were gated on and analyzed for CFSE, indicating efferocytosis. The 
percent of CFSE+ F4/80+ cells were called efferocytosis macrophages. The mean 
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fluorescence intensity (MFI) was determined. Efferocytosis index was calculated 
by multiplying the percent of efferocytosis macrophages by the MFI.  
Macrophages were cultured with 30nM siRNA for SCRAMBLE negative 
control or Sirpa (Dharmacon) with 1:1000 dilution of lipofectamine 3000 
transfecting agent (Thermo Fisher Scientific) for 24 hours prior to efferocytosis 
assay. Transfection took place in DMEM media containing no FBS or 
antibiotic/antimycotic.  
 In vivo efferocytosis was determined by collecting a skin biopsy from mice 
at day 5 post infection. Skin biopsy section was dissociated and processed for 
flow cytometry staining: surface staining for F4/80 followed by fixation and 
permeabilization for intracellular Ly6G staining. Macrophages were gated on and 
analyzed for Ly6G, indicating efferocytosis. Efferocytosis index was calculated by 
multiplying the percent of efferocytosis macrophages by the MFI normalized to 
the total number of macrophages.  
 
Immunofluorescence staining 
 Cells were cultured in 8-well chamber slides. Lipid raft staining was done 
using Vybrant AlexaFluor-488 lipid raft labeling kit (Thermo) on live peritoneal 
macrophages. Cells were incubated with AF488 labeled cholera toxin B (CTB) 
subunit, which binds to ganglioside GM1 that is found in lipid rafts. Cells were then 
labeled with an antibody to CTB which crosslinks the labeled lipid rafts to localize 
to areas on the plasma membrane. Following labeling, cells were fixed in 4% 
PFA for 15 minutes followed by washes with PBS. Slides were blocked with 3% 
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BSA for 1-2 hours at room temperature. Primary antibodies (against CD36 and 
SIRPα) were incubated at 1:100 for overnight at 4°C. Secondary antibodies (anti-
mouse or anti-rabbit AlexaFlour-647) were incubated at 1:200 for 1 hour at room 
temperature. Samples were mounted with the nuclear dye 4’,6-diamidino-2-
phenylindole (DAPI) antifade and sealed with a coverslip. Slides were visualized 
and pictures acquired on Nikon Eclipse Ci with filters for DAPI, GFP, and Texas 
Red and camera Nikon Ds-Qi2.  
 Proximity ligation assay was done using Duolink PLA kit (Sigma) on bone 
marrow neutrophils cultured in 8-well chambered cell culture slides (Corning). 
Neutrophils were pretreated with 10µM BLT1 antagonist U-75302 or 10nM LTB4. 
Neutrophils were co-cultured with GFP-MRSA at MOI 50:1 for 3 hours followed 
by inflammasome activation with 1µM nigericin for 1 hour. Cells were fixed with 
4% formaldehyde for 10 minutes and washed with PBS. Slides were blocked with 
3% bovine serum albumin (BSA) for 1 hour. Primary antibody incubation using 
Adipogen antibodies for NLRP3/NALP3 (NACHT, LRR and PYD domains-
containing protein 3) (Cryo-2) mouse antibody (1:200 dilution) and ASC 
(apoptosis-associated speck-like protein containing a carboxy-terminal CARD) 
(AL177) rabbit antibody (1:200 dilution) in blocking buffer for 2 hours at room 
temperature. Proximity ligation assay (PLA) staining protocol followed Duolink 
(Sigma) kit instructions. Slides were allowed to dry before mounting cells with 
ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific) and with a 
coverglass. Slides were visualized and pictures acquired on Nikon Eclipse Ci 
with filters for DAPI, GFP, and Texas Red and camera Nikon Ds-Qi2. 
51 
 
Statistical analysis 
 Data analysis was performed in GraphPad Prism software (San Diego). 
Statistical test used are listed in the figure legends. Briefly, Student’s t-test was 
used to compare two experimental groups. One-way ANOVA followed by Tukey 
multiple comparison correction was used to compare three or more groups. Two-
way ANOVA with repeated measured followed by Tukey multiple comparison 
correction was used to compare infection areas over time between two or more 
mouse groups. P values < 0.05 were considered significant. 
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75302 compared to WT mice treated with vehicle control (Figure 7B). To further 
determine the contribution of LTB4 in MRSA skin infection, an add-back 
experiment was performed. To do this, leukotriene deficient Alox5-/- mice were 
infected with MRSA and treated daily with topical ointments containing LTB4 or 
vehicle control. Alox5-/- mice had larger infection areas compared to WT mice, 
which was similar to observations with Ltb4r1-/- mice. 5-LO deficient mice treated 
daily with topical LTB4 ointment had a reduction in infection area, which was 
restored to levels seen in WT mice (Figure 7C). Alox5-/- mice also had higher 
bacterial burdens in the skin at day 1 and day 9 post infection and Alox5-/- mice 
treated with LTB4 ointment restored bacterial clearance (Figure 7D). Taken 
together, LTB4 is produced during MRSA skin infection and LTB4 actions 
mediated through BLT1 activation are needed to eliminate infection through 
controlling infection area size and bacterial burden.  
 
LTB4 promotes abscess architecture 
 MRSA skin infection is characterized by neutrophil recruitment and 
abscess formation. Since LTB4 is a known chemoattractant, histology analyses 
were performed to determine whether increased infection areas could be due to 
differences in immune cell populations. H&E sections from biopsies collected at 
day 1 post MRSA skin infection revealed no significant impairments in cell 
recruitment in Ltb4r1-/- or Alox5-/- mice compared to WT mice. However, the 
organization and structure of the abscesses were noticeably different (Figure 
8A). Cells recruited to the skin of WT mice developed an abscess architecture 
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infection, biopsy sections were used for immunohistochemistry (IHC) to detect 
neutrophils (Ly6G/C antibody) and macrophages (F4/80 antibody). WT, Ltb4r1-/-, 
and Alox5-/- mice all had abundant neutrophil recruitment, indicating no 
impairment in neutrophil recruitment to the skin. The abscess in WT mice was 
primarily composed of neutrophils, however, neutrophils from Ltb4r1-/-and Alox5-/- 
mice did not cluster into an abscess structure (Figure 9A). Treatment of Alox5-/- 
mice with topical LTB4 ointment restored neutrophil abscess formation.  
Macrophages were found in close proximity to the abscess in WT mice day 1 
post infection. However, macrophages from both Ltb4r1-/- and Alox5-/- mice lacked 
this association. Reduced macrophage interactions with the abscess in Alox5-/- 
were restored when mice were treated with topical LTB4 ointment (Figure 9B). 
This suggests that LTB4 plays a role in promoting abscess architecture and 
organization likely by mediating interactions between macrophages and 
neutrophils in the skin.  
Since LTB4 seemed important for mediating organized neutrophil abscess 
formation and architecture, the next question was how LTB4 affected neutrophil 
direction in the skin. In order to observe the dynamics of neutrophil migration in 
the skin, intravital microscopy imaging was used. Mice expressing GFP in 
myeloid cells, LysEGFP mice, were infected with MRSA and treated with an 
ointment containing no active ingredient, LTB4, or the BLT1 antagonist U-75302. 
At day 1 post MRSA skin infection, mice were prepared for two-photon 
microscopy and an area near the abscess was imaged for 30 minutes.  
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 Although all myeloid cells express GFP in this mouse model, it has been 
reported that neutrophils have brighter GFP signal than other myeloid cells [153], 
which was also identifiable in these experiments. Neutrophils in the skin of mice 
treated with vehicle-ointment (control) formed swarm-like clusters (Figure 10A). 
While neutrophils in the skin of mice treated with topical LTB4 ointment formed 
more swarm-like clusters than vehicle-treated mice, BLT1 antagonist treatment 
severely blunted these neutrophil accumulations. Additionally, although BLT1 
antagonist treatment did not affect velocity, neutrophil median velocity was 
increased when mice were treated with LTB4 (Figure 10B). Displacement values 
(the vector of distance from starting point A to ending point B) were similar 
between LTB4 treatment and control mice; however, displacement values were 
significantly reduced in mice treated with BLT1 antagonist (Figure 10C). The 
ratio of displacement to duration could be used to estimate directionality, 
indicating how far cells travel within a given time. Neutrophils that traveled a 
further distance away from the starting point in a given duration would have a 
greater ratio number than neutrophils that did not travel as far within a given 
duration. The ratio of displacement/duration was increased with LTB4 and 
decreased with BLT1 antagonist treatment compared to vehicle-control mice 
(Figure 10D). This suggested that neutrophils in LTB4 treated mice had a more 
directed migration whereas BLT1 antagonist treated mice had impaired 
migration, which recapitulated the observations seen in the movies.  
 Since LTB4 improved neutrophil direction in the skin and promoted abscess 
formation, the location of LTB4 in the skin during infection was next evaluated. 
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AA surrounding the abscess of WT mice infected with MRSA (Figure 11A). 
Since macrophages were also found in close proximity to the abscess, it is likely 
that macrophages and possibly other cell types near the periphery of the abscess 
are contributing to LTB4 production. It is also possible that LTB4 and other AA 
products are major players in promoting abscess architecture during MRSA skin 
infections.  
Since AA was found in high abundance surrounding the abscess, we next 
stained biopsy sections from naive and day 1 post MRSA skin infection for 5-LO 
by IHC. There was a high abundance of 5-LO+ cells near the abscess periphery 
(Figure 11B). Taken together, LTB4, as well as other 5-LO products, are likely 
found in high abundance surrounding the abscess, which likely promotes 
neutrophil direction to develop a well-structured abscess.  
 
MRSA killing involves LTB4-mediated NADPH oxidase activity  
 Mice deficient in 5-LO and BLT1 had higher bacterial burden compared to 
WT mice (Figure 7), and high bacterial burdens seemed to correlate with 
impaired abscess structure. We then decided to determine the mechanism by 
which LTB4 enhances MRSA antibacterial functions in the skin. First IHC for 
gram stains were analyzed to determine where bacteria were located in the skin 
during infection. MRSA were located within neutrophils located inside the 
abscess in the skin of WT mice (Figure 12). Ltb4r1-/- and Alox5-/- mice had many 
clusters of extracellular MRSA colonies throughout the skin. Treating Alox5-/- 
mice with topical LTB4 ointment restored phagocytosis of bacteria. This suggests 
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compared to WT mice (Figure 13B). Additionally, topical LTB4 ointment reduced 
infection areas and improved bacterial clearance in WT mice but not in Cybb-/- or 
apocynin-treated mice. H&E analysis of tissue biopsy sections taken at day 1 
post MRSA skin infection revealed that treating mice with apocynin disrupted 
abscess architecture, which impaired effective bacterial containment and 
clearance (Figure 13C). This shows that NADPH-oxidase activity is necessary 
for MRSA killing and that topical LTB4 treatment did not revert MRSA killing with 
NADPH-oxidase deficiency. Also, this suggests that abscess architecture may 
also be mediated through a ROS-dependent process.  
 
LTB4/BLT1 promotes IL-1β production  
 LTB4 is an important molecule involved in the production of cytokines and 
other inflammatory mediators [66, 67]. A custom multiplex assay was created to 
measure multiple inflammatory mediators simultaneously in skin biopsy 
homogenates. Skin biopsy samples from WT and Ltb4r1-/- mice collected from 
naive uninfected skin, day 1 and day 9 post MRSA infection revealed that several 
inflammatory mediators are decreased in Ltb4r1-/- mice during infection compared 
to WT mice (Figure 14A). Importantly, day 1 post infection, Ltb4r1-/- had lower 
expression of IL-1β (Figure 14B), which is important for abscess formation 
during S. aureus skin infection [170]. Additionally, chemokines such as CXCL2 
(Figure 14C) were enhanced in Ltb4r1-/- at day 1 post infection and there was no 
difference in ICAM1 expression (Figure 14D). Since CXCL2 and ICAM1 are 
important for neutrophil recruitment, observing no impairments in neutrophil 
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a pro-cytokine, which requires maturation [121]. MRSA skin infection induced 
expression of Il1b (Figure 15A). MRSA-infected mice treated with LTB4 ointment 
did not significantly alter Il1b expression, however BLT1 antagonist U-75302 
treatment blunted Il1b expression during MRSA skin infection. ELISA data 
confirmed that IL-1β is produced in the skin of mice during MRSA skin infection 
and that LTB4 treatment increased levels of IL-1β (Figure 15B). Increased levels 
of IL-1β despite no differences in gene expression suggest that LTB4 may be 
involved in promoting IL-1β processing. BLT1 antagonist treatment and mice 
deficient in BLT1 had lower levels of IL-1β at day 1 post MRSA skin infection 
compared to WT mice. To determine whether LTB4 influences the kinetics of IL-
1β during MRSA skin infection, we employed the IL-1β reporter mouse 
pIL1DsRED [151] using IVIS in vivo imaging technology. The pIL1DsRED mice 
were infected with MRSA and treated with a topical ointment containing BLT1 
antagonist U-75032 or vehicle control. Mice were imaged by IVIS for DsRed 
signal every day post infection for 5 days (Figure 15C). Signal of DsRed, was 
highest at days 1 and 2 post infection and decreased by day 3 of infection 
(Figure 15D). This suggests that IL-1β is expressed early during MRSA skin 
infection. BLT1 antagonist treatment had minimal expression of DsRed at all 
points measured during infection suggesting that LTB4 was important for Il1b 
expression during MRSA skin infection.  
 Next, we aimed to identify which cells produced IL-1β during MRSA skin 
infection. The pIL1DsRED mice were infected with MRSA and treated with or 
without BLT1 antagonist U-75302. BLT1 antagonist treatment did not alter the 
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fluorescence microscopy to determine associations of NLRP3 and ASC using 
PLA. Close proximity of these proteins resulted in red fluorescence. Neutrophils 
from WT mice were cultured with GFP-expressing MRSA for 3 hours followed by 
inflammasome activation with nigericin for 1 hour. Neutrophils with no treatment 
did not show interactions between NLRP3 and ASC (Figure 17A). Neutrophils 
co-cultured with MRSA induced minimal, but significant, inflammasome 
assembly. Inflammasome-activated (with nigericin treatment) neutrophils showed 
significantly higher inflammasome assembly compared to cells only, and LTB4 
treatment further promoted inflammasome assembly. BLT1 antagonist U-75302 
treatment inhibited inflammasome assembly (Figure 17B-C). These results 
suggest that LTB4/BLT1 is important for Il1b expression and that LTB4 may be an 
important mediator in regulating inflammasome assembly and activation allowing 
for mature IL-1β production.  
 
Macrophages are critical for LTB4 production  
 Although neutrophils are a major cell type recruited to the skin during 
MRSA skin infection, macrophages were observed surrounding the neutrophil 
abscess. Perivascular macrophages have been shown to be important for 
neutrophil recruitment to the skin [165]. The role of resident macrophages in the 
skin was during MRSA infection was next evaluated. MMDTR mice were used to 
investigate this role. MMDTR mice are Csf1rLsL-DTR-mCherry mice crossed with 
LysMcre [152] and are described in more detail in the “Materials and Methods”. 
Macrophage depletion was confirmed by two methods. The first method was to 
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DT. PBS-treated MMDTR showed abundant neutrophil recruitment and abscess 
formation, shown as Ly6G-AlexaFluor-488 (Ly6G-AF488) green staining, 
whereas DT-treated mice had fewer neutrophils and the neutrophils present in 
the skin failed to develop into an abscess (Figure 19A). Macrophages (mCherry) 
shown in red were found nearby the neutrophilic abscess in PBS mice, but were 
not present in DT-treated mice. Since fewer neutrophils were observed by 
immunofluorescence staining in macrophage-depleted mice, this finding was 
confirmed by flow cytometry. MMDTR mice treated with DT had fewer neutrophils 
in the skin at day 1 post MRSA skin infection compared to PBS treated MMDTR 
mice (Figure 19B). This suggests that macrophages are necessary for neutrophil 
recruitment and for promoting abscess architecture. Since our data show that 
LTB4 is an important mediator involved in controlling MRSA skin infection, LTB4 
was measured in the skin from MMDTR mice 6 hours and day 1 post infection. 
Macrophage depletion resulted in lower production of LTB4 compared to PBS-
treated mice (Figure 19C), demonstrating that macrophages were an important 
player in promoting LTB4 production.  
In order to determine whether a lack of LTB4 in macrophage depleted 
mice was contributing to poor host defense, DT-treated MMDTR mice were 
treated with a topical ointment containing LTB4. Macrophage depletion resulted in 
larger infection area compared to control mice, but topical LTB4 treatment on 
macrophage-depleted mice reduced infection area size (Figure 20A). 
Macrophage depletion resulted in higher bacterial burdens in the skin, which was 
reduced when MMDTR mice were treated with LTB4 (Figure 20B). Topical LTB4 
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along with other factors, are needed for orchestrating abscess formation during 
MRSA skin infection.  
The next question was whether macrophage depletion affected chemokine 
and cytokine production. Multiplex assays were conducted on skin biopsy 
homogenates from PBS-vehicle and DT-treated MMDTR mice that were treated 
with or without topical LTB4 ointment. Macrophage depletion reduced the levels 
of IL-1β at day 1 post infection, which was restored with topical LTB4 treatment 
(Figure 21A). Expression of neutrophil chemotactic molecules (CXCL2, P-
selectin, and ICAM1) was either unchanged or expressed at higher levels in 
macrophage-depleted mice (Figure 21B-D). Since macrophages were important 
for neutrophil recruitment as determined by H&E analysis, but expression of 
cytokines, chemokines, and adhesion molecules were not all downregulated, this 
suggests that neutrophils may be capable of recruiting to the site of infection. 
This suggests other signals provided by macrophages, such as LTB4, or having 
direct contact with macrophages is necessary for recruitment and abscess 
formation.  
Macrophage depletion resulted in lower LTB4 production and reduced 
neutrophil recruitment. Neutrophils are also capable of producing LTB4 at the site 
of injury [81]. In order to determine the role and contribution of neutrophils during 
MRSA skin infection, WT mice were treated with αLy6G (clone 1A8) depleting 
antibody or IgG control prior to MRSA skin infection. Infection areas were 
measured at day 1 post infection, and mice depleted of neutrophils had larger 
infection areas compared to IgG-controls (Figure 22A). Biopsies were taken at 6 
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and abscess formation but mice treated with αLy6G antibody had drastically 
fewer cells in the skin (Figure 22C). Additionally, pockets of extracellular bacteria 
were observed in neutrophil-depleted mice. These data suggest that 
macrophages and neutrophils are contributing to LTB4 production in the skin 
during infection. However, since other cell types can produce LTB4, more 
experiments are needed to elucidate the contribution from specific cell types 
during MRSA skin infection. Nonetheless, since LTB4 treatment did not fully 
restore macrophage-depleted mice, this demonstrates the importance of the 
interaction between macrophages and neutrophils that require LTB4.  
 
LTB4 has therapeutic potential for treating MRSA skin infections 
 Due to the beneficial role of LTB4 mediating neutrophil abscess 
architecture and promoting NADPH-oxidase mediated killing of MRSA, the next 
question was whether LTB4 has therapeutic potential for treating MRSA skin 
infections. Therefore, we further pursued our studies using an antibiotic that is 
commonly used to treat gram-positive bacterial infections.  
 Vancomycin (1%) was emulsified in an ointment and used to treat mice 
infected with MRSA. Vancomycin is used as an intravenous therapy [172] with 
limited skin penetration. Topical vancomycin preparation had no significant effect 
on infection area (Figure 23A). LTB4 ointments had a slight improvement in 
reducing infection area, and the combination ointment with LTB4 and vancomycin 
had no effect relative to LTB4 ointment alone. Mupirocin (2%) is a topical 
ointment antibiotic that is used to treat minor skin infections [172]. Mice treated 
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the same mouse throughout infection, which aided in determining how effective 
the ointment treatments were. LTB4 ointment and mupirocin ointments alone had 
a slight reduction in infection area compared to WT with no treatment (Figure 
24A). The combination ointment containing both LTB4 and mupirocin greatly 
reduced infection area and was more effective than the single-agent ointments. 
The reduction in infection area correlated with a reduction in bacterial burden 
(Figure 24B). The combination ointment was more successful in promoting 
bacterial clearance than the single agents alone, which was determined by CFU 
counts from skin biopsy homogenates and by detecting bioluminescence from 
bioluminescence-expressing MRSA (Figure 24C). Lastly, H&E sections from 
biopsies collected at day 1 post MRSA skin infection were evaluated for abscess 
structure. LTB4 and mupirocin ointments promoted a defined abscess structure; 
however the combination ointment developed a smaller, more compact abscess 
structure (Figure 24D). This suggests that LTB4 in combination with topical 
antibiotic mupirocin therapy is a promising strategy to treat MRSA skin infections.  
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skewing towards some lipoxygenase products, including LTB4, in the skin of 
diabetic mice during MRSA skin infection. 
 We then determined the expression of Alox5 in naive and day 1 infected 
skin from CT and STZ mice. There was higher expression of Alox5 in the skin of 
diabetic mice, even in the absence of infection (Figure 29A). Although MS 
analysis showed elevated levels of LTB4 in the skin, these data were confirmed 
using EIA. Little LTB4 was detected in naive skin from both CT and STZ mice. 
Upon MRSA skin infection, LTB4 production was elevated in the skin but diabetic 
mice produced significantly more LTB4 than CT mice (Figure 29B). These data 
demonstrate that diabetic mice produce exaggerated levels of LTB4 in the skin 
during MRSA infection independent of exaggerated 5-LO expression. This 
suggests that the activation of various LT synthesis enzymes may be altered in 
diabetic mice during MRSA skin infection compared to nondiabetic mice. 
 
Uncontrolled BLT1 actions drive poor host defense in diabetic mice 
Since LTB4 can signal through one of two receptors, BLT1 and BLT2, the 
expression of these receptors was investigated. Expression of Ltb4r1 was higher 
in the skin of diabetic mice at day 1 post infection (Figure 30A). No differences 
were observed in expression of Ltb4r2 between diabetic and nondiabetic mice 
(Figure 30B). Receptor expression of BLT1 and BLT2 was also confirmed 
determined by mean fluorescence intensity (MFI) measured by flow cytometry 
analysis on skin biopsy sections in naive, and days 1, 3, 9 post infection. MFI of 
BLT1 was higher in the skin of diabetic mice than nondiabetic mice at all time 
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affinities for BLT2 than LTB4, so BLT2 antagonist treatment is not specific for 
inhibiting LTB4 actions exclusively. However, BLT2 antagonist treatment did not 
worsen infection area or disrupt healing in diabetic mice with the dose tested. 
Therefore, we focused our research effects by studying the role of LTB4 and 
BLT1 actions and how this influences host defense in diabetic mice.  
 To further evaluate the therapeutic potential of blocking BLT1 in the skin of 
diabetic mice, mice were infected with bioluminescent-expressing MRSA. This 
allowed for in vivo bioluminescence imaging (BLI) for bacterial burden 
quantification in the skin throughout the infection in the same animal. Infection 
areas of diabetic mice treated with BLT1 antagonist U-75302 were smaller than 
those observed in diabetic mice treated with vehicle-control (Figure 33A). IVIS in 
vivo imaging revealed that diabetic mice were unable to eliminate bacteria, 
whereas nondiabetic mice and diabetic mice treated with BLT1 antagonist 
demonstrated bacterial clearance overtime (Figure 33B-C). To confirm that the 
BLT1 antagonist U-75302 was effective in restoring host defense in diabetic 
mice, the same treatment protocol was used in diabetic NOD mice. Similar to 
diabetic STZ mice, diabetic NOD mice treated with BLT1 antagonist had smaller 
infection areas compared to diabetic mice receiving no treatment (Figure 33D). 
These data show that BLT1 antagonist treatment improved host defense of 
diabetic mice during MRSA skin infection.  
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observed surrounding the abscess of CT mice, which was not apparent in STZ 
mice. We next determined whether diabetic mice were unable to produce 
fibrin/collagen during infection, which may impair abscess formation. Histology 
sections were stained with Masson's trichrome blue (Figure 35A) and PTAH 
(Figure 35B) stains. Masson’s trichrome blue stains collagen in blue. PTAH stain 
labels fibrin in blue/black and collagen in pink. The fibrous capsule in CT mice at 
day 1 post MRSA skin infection appeared to be composed primarily of collagen. 
There was irregular collagen deposition observed in the skin of diabetic mice at 
day 1 post MRSA skin infection. Although fibrin was reported to be a major 
component of the abscess capsule [128] , minimal fibrin staining was observed in 
the skin of MRSA-infected mice. However, more staining is required to 
differentiate the types of collagen and fibrin to determine the exact composition of 
the abscess in the skin during MRSA skin infection. Nonetheless, the irregular 
deposition of these fibrous molecules in the skin of diabetic mice may be 
associated with poor abscess formation.  
Next, we evaluated what mediators were altered in the skin of diabetic 
mice and whether BLT1 antagonist treatment influenced the production of these 
mediators. To do this, skin biopsy homogenates were tested in a multiplex assay 
to detect multiple analytes at once (Figure 36A). Expression of the adhesion 
molecule ICAM1 (Figure 36B) was enhanced, while CXCL2 (Figure 36C) and 
receptor for advanced glycation end-products (RAGE) (Figure 36D) were 
downregulated in the skin of diabetic mice at day 1 post infection. These are 
potent inflammatory mediators influencing host defense through activating 
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producing cells. No significant differences were observed in DsRED MFI in 
macrophages or neutrophils in the skin at day 1 post infection between CT and 
STZ mice (Figure 37A-B). Another approach to determine the contribution of IL-
1β signaling in the skin was through pharmacological inhibition of MyD88, an 
adaptor required for IL1R signaling. Diabetic and nondiabetic mice were treated 
daily with a topical ointment containing MyD88 blocking peptides or non-targeting 
control peptides during MRSA skin infection. Nondiabetic control mice treated 
with the MyD88 peptide had worse infection compared to control peptide. 
However, diabetic mice treated with the MyD88 peptide had no significant effect 
on infection area compared to diabetic mice treated with the control peptide 
(Figure 37C). Although MyD88 blocking peptide prevents signaling of other TLR 
and IL1 receptor family members, and since diabetic mice were unchanged, it 
suggests that other mediators may play a more significant role in poor host 
defense. Importantly, while IL-1β may play a significant role in abscess formation 
during MRSA skin infection in nondiabetic mice, IL-1β in the skin of diabetic mice 
is not deficient and that other mechanisms are involved in poor host defense in 
diabetic mice. 
 
Uncontrolled neutrophil and macrophage responses 
 The next step was to determine how abundant LTB4 levels in the skin of 
diabetic mice altered the dynamics of cell migration during MRSA skin infection. 
To do this, MRSA-infected diabetic and nondiabetic mice with GFP-expressing 
myeloid cells (LysEGFP) were used for intravital microscopy. Diabetic mice were 
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treated with or without a topical ointment containing BLT1 antagonist U-75302.  
Infection areas in skin flaps of anesthetized mice were imaged by intravital 
microscopy for 30 minutes (Figure 38A). Neutrophils in CT mice formed swarm-
like accumulations, whereas neutrophils in diabetic mice showed faster speed 
and lacked apparent direction (Figure 38B). Neutrophils in diabetic mice treated 
with BLT1 antagonist treatment surprisingly had even faster speed than diabetic 
neutrophils and the swarm-like accumulations were restored. Also, the 
displacement of neutrophils was longer in neutrophils from diabetic mice and 
BLT1 antagonist further increased displacement values (Figure 38C). The ratio 
of displacement to duration revealed that neutrophils from diabetic mice treated 
with BLT1 antagonist was higher indicating more directed migration than 
neutrophils in diabetic mice (Figure 38D). Since the multiplex assay revealed 
that BLT1 antagonist restored many of the chemokine and cytokine profile during 
MRSA skin infection, it is likely that blocking BLT1 allowed for neutrophils to 
better sense the other chemoattractant gradients in the skin to improve abscess 
formation.  
 Next, we decided to investigate whether the diabetic milieu influenced the 
localization of neutrophils and macrophages in the infected skin. IHC slides 
stained for a neutrophil marker (Ly6G/C) revealed little to no neutrophils in the 
skin of naive mice. At day 1 post MRSA skin infection, we detected a great 
abundance of neutrophils, which were organized within an abscess in the skin of 
nondiabetic mice (Figure 39A). Similar to what H&E slides revealed, diabetic 
mice had a greater abundance of neutrophils, but lacked organized abscess 
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abundance of neutrophils in the skin, which was reduced with BLT1 antagonist 
treatment (Figure 39B).  
 Macrophages associated around the periphery of the neutrophil abscess 
in nondiabetic mice. IHC staining for F4/80 revealed that macrophages were 
located in the skin at the various time points after infection. A population of 
tissue-resident macrophages was observed in the skin of naive skin. At day 1 
post MRSA skin infection, macrophages in control mice were found along the 
periphery of the abscess and in diabetic mice, macrophages were found at more 
distant locations (Figure 40A). BLT1 antagonist treatment restored the 
interactions of macrophages with the neutrophil aggregates. At day 9 post MRSA 
skin infection, control mice had relatively more macrophages present in the skin 
compared to naive skin, likely promoting tissue remodeling and repair after 
infection (Figure 40B). Interestingly, there were more macrophages in the skin of 
diabetic mice at day 9 post infection compared to control mice, which was greatly 
reduced with BLT1 antagonist treatment.  
 
Macrophages in diabetic mice are detrimental to host defense 
  In order to better understand the role of skin-resident macrophages during 
MRSA skin infection in diabetic mice, macrophages were depleted prior to 
infection using MMDTR mice. Diabetic and nondiabetic MMDTR were treated 
with diphtheria toxin (DT) or PBS-vehicle control. Initially, we performed 
immunofluorescence to determine whether macrophages influence neutrophil 
migration to the site of infection. Immunofluorescence sections from skin biopsy 
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CCL2 was highly expressed in the skin of diabetic mice but was reduced when 
macrophages were depleted (Figure 43D). This suggests that macrophages in 
the skin of diabetic mice produce inflammatory mediators that promote 
exaggerated LTB4 production and subsequently overwhelming inflammation and 
poor host defense.  
 
Uncontrolled cell death and poor cell clearance in diabetic mice 
 S. aureus skin infections are known to induce cell death [128]. Neutrophil 
recruitment and cell death are typical events that occur during infection or injury. 
If apoptotic cells are not cleared effectively, they become necrotic and produce 
DAMPs that elicit more inflammation. Here, we are hypothesizing that either 
exaggerated cell death or poor clearance of dead cells leads to secretion of 
DAMPs that further enhance inflammation. Histology sections from skin biopsies 
from MRSA-infected diabetic and nondiabetic mice were stained by TUNEL 
assay to visualize dead cells in the skin (Figure 44A). Very few cells in naive 
skin were apoptotic. At day 1 post infection there were increased levels of 
apoptotic cells in the skin of nondiabetic mice but were much higher in the 
diabetic mice. At day 9 post infection, there were few apoptotic cells in the skin of 
nondiabetic mice, the inflammatory process was resolved and the dead cells 
properly eliminated. However, diabetic mice still had great numbers of apoptotic 
cells in the skin, which was reduced with topical BLT1 antagonist treatment. 
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with effective apoptotic cell clearance, leading to high apoptotic cell burden. More 
experimentation is necessary to determine the contribution of receptor 
expression by the various cell populations in the skin.  
To test whether macrophages from diabetic mice had impaired apoptotic 
cell clearance, in vitro efferocytosis assays were performed. Peritoneal 
macrophages from diabetic and nondiabetic mice were cultured with MRSA-
infected apoptotic cells (IACs) that were prepared from bone marrow neutrophils 
isolated from diabetic and nondiabetic mice. Macrophages from nondiabetic mice 
engulfed similar levels of IACs regardless whether the cells were from diabetic or 
nondiabetic mice. Similarly macrophages from nondiabetic mice engulfed similar 
levels of nondiabetic and diabetic sourced IACs (Figure 47A). In order to 
determine whether impaired efferocytosis occurs in vivo, biopsy sections were 
collected from diabetic and nondiabetic mice at day 5 post infection. Dissociated 
biopsy sections were processed for flow cytometry analysis by labeling 
macrophages with F4/80-PECy7 antibody followed by intracellular staining for 
Ly6G-AF488. Macrophages were gated on and analyzed for intracellular Ly6G, 
indicating efferocytosis. There were a higher percentage of macrophages 
observed in the skin of diabetic mice compared to nondiabetic mice. However, 
the efferocytosis index was significantly lower in macrophages from diabetic 
mouse skin compared to control (Figure 47B).  
There are reports phagocytic receptors and SIRPα associating with lipid 
rafts to facilitate or inhibit efferocytosis, respectively [178, 179]. Lipid rafts are 
subdomains in the plasma membrane. Lipid rafts are thought to enhance the 
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using anti-cholera toxin B antibody (green fluorescence) and anti-SIRPα antibody 
(red fluorescence). Whereas SIRPα was not localized in lipid rafts in 
macrophages from nondiabetic mice, SIRPα appeared to be in lipid rafts in 
macrophages from diabetic mice (Figure 47C). This suggests that the 
expression and cellular location and organization of SIRPα could be playing a 
major role in the impaired efferocytosis of IACs by macrophages from diabetic 
mice. To determine whether elevated expression of SIRPα was impairing 
efferocytosis, macrophages from diabetic and nondiabetic mice were treated with 
silencing RNA (siRNA) to knockout SIRPα. Treating macrophages with siSirpa 
showed higher efferocytosis of IACs compared to macrophages treated with 
scrambled control (Figure 47D). More experimentation is required to determine 
the contribution of SIRPα and other receptors in poor efferocytosis by 
macrophages in diabetic mice.  
 Taken together, macrophages in the skin of diabetic mice were 
detrimental to infection through promoting excessive LTB4 production, neutrophil 
recruitment and cell death, and macrophages had impaired clearance of dead 
cells, contributing to overwhelming inflammation.  
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DISCUSSION 
Part I - LTB4 is necessary for host defense 
LTB4 promotes antimicrobial effector functions  
 LTB4 promotes phagocytosis and killing of many types of pathogens [53, 
95, 97-99, 101, 103]. In vitro assays with bone marrow neutrophils and peritoneal 
macrophages challenged with LTB4 did not affect MRSA killing (data not shown). 
This may be a pathogen-specific effect or possibly that the use of bone marrow 
neutrophils and peritoneal macrophages are not appropriate cells to model skin 
infection. Bone marrow neutrophils have a more immature phenotype compared 
to neutrophils that are recruited to the skin which are in a more active state [181]. 
Likewise, peritoneal macrophages may not exhibit the same phenotype as 
macrophages located in other sites [182], such as with the skin. However, in vivo, 
LTB4 was necessary to promote bacterial killing in the skin, which is likely 
mediated through NADPH oxidase activity. LTB4 has been shown to induce 
p47phox expression and translocation to the membrane allowing NADPH oxidase 
assembly in vitro and in vivo [106]. MRSA killing required NADPH oxidase 
activity and topical LTB4 application did not restore MRSA killing. Although there 
are other mechanisms utilized by phagocytes to kill bacteria, such as the 
production of antimicrobial peptides and RNS. LTB4 has been shown to induce 
the production of NO and defensins such as CRAMP in mice and LL37 in human 
neutrophils [103, 109, 112]. We cannot exclude the role of other antimicrobial 
molecules during MRSA skin infection that are functioning directly or indirectly of 
LTB4 actions. 
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 Enhancing beneficial inflammation is important for promoting antimicrobial 
effector functions to eliminate infections. However, wound healing is necessary to 
restore homeostasis to the tissue environment. Eicosanoids are involved in 
wound healing mechanisms [183]. BLT2 signaling mediated through 12-HHT and 
12-HETE have been shown to promote keratinocyte migration and promote 
VEGF expression which aid in wound healing [54, 55]. Other eicosanoids that are 
involved in wound healing include specialized pro-resolving mediators that 
include lipoxins, resolvins, and protectins [184]. More experimentation is required 
to elucidate the roles of these various eicosanoids during infection and to 
determine whether the balance of these mediators is altered in the context of 
diabetes.  
 
Source of LTB4 in the skin 
 Macrophages and neutrophils are major sources of LTB4 production 
during inflammatory response [30]. The relative contributions of individual cells in 
LTB4 production are not fully understood. The MMDTR approach allows for 
selective depletion of monocytes and macrophages with diphtheria toxin 
treatment (DT), which does not deplete other cells such as dendritic cells or 
neutrophils [152]. DT treatment resulted in lower levels of LTB4 produced in the 
skin. Neutrophil depletion with Ly6G (clone IA3) depleting antibodies also 
resulted in lower LTB4 levels, suggesting that neutrophils are also an important 
source. However, the contribution of LTB4 production by other cell types cannot 
be ruled out such as the contribution by dendritic cells [185] and other cell types 
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participating in LTB4 production by transcellular biosynthesis [32]. Further, 
experiments depleting both cell types are needed to unveil whether other cell 
types are indeed required for LTB4 production during infection. Also, it is likely 
that LTB4 is produced from multiple sources and requires several cell populations 
for abundant production. Perivascular macrophages are important for neutrophil 
recruitment to the skin during S. aureus infection [165]. Circulating neutrophils 
extravasated in close proximity to perivascular macrophages. We observed that 
macrophage depletion in MMDTR mice resulted in remarkably fewer Ly6G+ 
neutrophils in the skin during MRSA skin infection. Since neutrophils also 
produce LTB4, it is unclear whether the lack of macrophages leading to poor 
neutrophil recruitment is the cause of LTB4 or that macrophages produce a 
considerable amount of LTB4 in the skin.  
 
LTB4 and abscess architecture 
MRSA skin infections characteristically develop abscesses [128]. Abscess 
formation in response to S. aureus infection is thought to occur in stages 
resulting with a central core of live bacteria encased by eosinophilic 
pseudocapsule surrounded by layers of live and dead neutrophils [186]. 
However, S. aureus abscess might differ dependent on the infected organ 
formation involves complex sequential regulatory steps that lead to migration of 
phagocyte, cell death, elimination of dead cells and compartmentalization and 
there are variances depending on anatomical site. Furthermore, abscesses in the 
kidneys are fatal without treatment whereas abscesses in the skin are necessary 
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for effective containment and prevents dissemination [170]. We did not observe 
dissemination or lethality in our infection model with any genotype or treatment 
condition. This could be due to the relatively low infection inoculum used in our 
skin infection model compared to others’ (3x106 vs. 1-2x107) [187, 188]. 
Alternatively, there could be other molecules involved in the dissemination of 
bacteria that are unrelated to LTB4/BLT1 effects. Future experiments are needed 
to evaluate the factors involved in bacterial dissemination from a skin infection.  
Additionally, macrophages were found in close proximity to the abscess 
during MRSA skin infection. However, adding back LTB4 to macrophage-
depleted mice partially restored abscess formation by promoting better neutrophil 
clustering. This suggests that the presence of macrophages in the skin may be 
necessary for abscess architecture, or that macrophages are the primary source 
of other chemoattractants that are necessary for abscess formation. Despite this, 
since macrophage depletion resulted in worse infection outcome, it is likely that 
macrophages are either the source of LTB4 or provide the signals required for 
LTB4 production and other inflammatory mediators that are necessary for 
controlling MRSA skin infection. Nonetheless, these results demonstrate an 
important role of macrophages in orchestrating effective host defense 
mechanisms during MRSA skin infection. 
Before an abscess is formed, neutrophils need to migrate to the site of 
infection. This requires a series of steps including rolling, adherence, and 
transmigration [68]. LTB4 is known to be chemotactic for neutrophils as well as 
other cell types [75, 189]. Inhibition of the enzyme that produces LTB4, 
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leukotriene A4 hydrolase (LTA4H) with an inhibitor such as bestatin results in less 
neutrophil recruitment and higher S. aureus burden and infection area [137]. 
However, bestatin is a non-selective inhibitor that also blocks the activity of 
peptidases. Bestatin has been shown to promote many anti-inflammatory effects, 
and has implications as use as an anti-inflammatory agent [190]. Therefore, the 
exact role of LTB4 in the skin host defense remained to be determined. In 
different models of inflammatory diseases, such as arthritis, BLT1 is required for 
neutrophil recruitment to the joints [171] or in a model of spinal-cord injury [67]. 
However, in a model of tissue injury [81] and in our MRSA skin model there was 
no initial recruitment impairment in Ltb4r1-/- neutrophils to the site of injury. These 
suggest the molecules required for rolling, adherence, and transmigration are 
unaffected by LTB4/BLT1 in MRSA skin infection models. Alternatively, the role of 
LTB4/BLT1 in neutrophil recruitment may differ depending on type of 
inflammatory stimuli and location (such as sterile inflammation of arthritis in the 
joint vs. infectious pathogen in the skin). However, the ability of Ltb4r1-/- 
neutrophils to be directed to a local point in the skin was inhibited as shown in 
both our MRSA infection model as well as in a sterile injury model [81], 
suggesting LTB4 functions to provide direction. LTB4 has been shown to act as a 
signal-relay signal promoting enhanced neutrophil migration towards other 
chemotactic molecules such as fMLP [78]. In additions, LTB4 could also 
participate in a hierarchical role of lipid-cytokine-chemokine, which enhances 
cytokine production that in turn enhances chemokine-mediated recruitment of 
neutrophils [171].  
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IL-1β has been shown to be important for abscess formation [170]. Since 
BLT1 antagonist treated mice and Ltb4r1-/- mice had less IL-1β produced, it is 
likely that LTB4 mediates ll1b expression and inflammasome activation to 
promote IL-1β production. IL-1β processing through NLRP3 inflammasome 
activation requires two signals: 1) TLR activation and gene expression and 2) 
NLRP3 inflammasome assembly and activation. LTB4 is known to enhance NFκB 
activation [60]. Our data also show that LTB4 promotes inflammasome assembly 
and activation. BLT1 antagonist treatment blocked the expression of Il1b and 
mature IL-1β levels. PLA on neutrophils activated for inflammasome assembly 
revealed that LTB4 promoted more associations of NLRP3 and ASC, whereas 
BLT1 antagonist inhibited inflammasome assembly. In S. aureus skin infection, it 
is thought that the majority of IL-1β production is mediated through NLRP3 
inflammasome activity. MRSA produces toxins, such as α-hemolysin that have 
been shown to activate NLRP3 [191]. Additionally, proteases produced by 
neutrophils and bacteria are able to cleave pro-IL-1β into mature IL-1β 
independently of inflammasome activation [121]. We did not evaluate whether 
toxins produced by MRSA or proteases were involved in IL-1β processing during 
skin infection. Our experiments here cannot rule out other non-canonical IL-1β 
processes or inflammasome activation.  
 
Therapeutic potential of enhancing LTB4/BLT1 actions 
In the era of antibiotic resistant bacteria, a new therapeutic strategy that 
incorporates host-derived products along with effective antibiotic therapy are 
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desperately needed. Immunomodulatory therapies to boost host immune 
functions are potential strategies better treat infections [192]. There are many 
potential advantages to using LTB4 in immunotherapeutic protocols, such as: 1) 
compared with generation of recombinant proteins, LTB4 can be readily and 
inexpensively synthesized with a high degree of purity. 2) The short half-life of 
LTB4 could provide flexibility and precision in controlling pro-inflammatory 
actions. 3) LTB4 administration to humans have been well-tolerated [193, 194], 
and 4) LTB4 amplifies initial antimicrobial responses by enhancing bacterial 
recognition and phagocytosis [60, 104, 106], release of ROS [106, 114], IL-1β 
levels, and pro-inflammatory responses through MyD88 expression and NFκB 
activation [106, 114]. 
 Due to these immunostimulatory roles LTB4 exerts on phagocyte effector 
functions, targeting LTB4/BLT1 has a potential for enhancing beneficial 
inflammation to better control MRSA skin infections. Our data show that LTB4 
and mupirocin combination ointment promoted faster MRSA clearance compared 
to single agent ointments and no treatment. How LTB4 and mupirocin function 
together to promote synergistic activities remains to be determined. Antibiotics 
have been shown to synergize with antimicrobial peptides, which improves 
bacterial clearance [195]. Antibiotics may promote other immune activation 
besides bacterial killing. Likewise, LTB4 has been shown to induce expression of 
LL37 [112], which has been shown to improve antibiotic therapy [196]. More 
research is needed into ointment stability and treatment regime to promote 
optimal infection control without inducing host damage.  
121 
 
Treatment protocols employing exogenous LTB4 can be greatly beneficial 
to patients known to exhibit poor host defense and attenuated LT synthesis such 
as in malnutrition [197], cigarette smoking [198], vitamin D deficiency [199], HIV 
infection [200], and bone marrow transplantation [201]. Adding back LTB4 to 
immunodeficient patients could potentially restore phagocyte response and favor 
appropriate host defense. Additionally, small amounts of exogenous LTB4 
treatment are able to boost effector functions in immunocompetent WT mice. In a 
model of Streptococcus pneumoniae lung infections, aerosolized LTB4 treatment 
restores host defense mechanisms in Alox5-/- mice and enhancing effector 
functions in WT mice [116]. Intravenous injection of LTB4 in macaques enhances 
plasma levels of the antimicrobial peptides α-defensins. Plasma from the treated 
macaques can neutralize pathogens ex vivo [202]. LTB4 treatment during 
influenza virus infection reduces viral titers compared to untreated mice [111]. 
The reduction in viral titers correlates with enhanced levels of the cathelicidin-
related antimicrobial peptide (CRAMP). Neutrophils are a major source of 
CRAMP so when mice are depleted of neutrophils, exogenous LTB4 treatment 
during influenza infection is unable to control viral load [111]. 
A potential pitfall is that LTB4 might lead to overwhelming recruitment of 
neutrophils, which may contribute to tissue injury. Also, the stability and safety of 
LTB4 in vivo is a concern, but it has been shown that bronchoscopy instillation of 
LTB4 into the airways of normal human subjects elicited a marked influx of 
neutrophils. Inhalation of LTB4 proved to be well tolerated and did not cause any 
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and mupirocin was synergistic for better treating MRSA skin infection. This 
demonstrates potential for LTB4 to be used as an immunostimulatory therapy to 
treat antibiotic-resistant infections. 
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Part II - LTB4 complicates host defense in diabetes 
Diabetes model 
 Both people with Type 1 and Type 2 diabetes are more susceptible to 
infections. One mouse model to study T1D is the NOD mouse, however NOD 
mice are known to have impaired immune cell activation and functions [173, 
174]. These impaired immune functions may drive the minor differences 
observed between the NOD and STZ models during MRSA skin infection, such 
as dbNOD mice displaying a more delayed response to MRSA skin infection 
compared to the kinetics observed in STZ mice. STZ is a model of T1D, in that 
mice develop hyperglycemia and very low insulin levels [162] however, STZ-
treated diabetic mice lack the autoimmune component of T1D. The benefit of 
utilizing STZ to induce diabetes allowed for comparisons how a diabetic 
environment alters phagocyte antimicrobial function during MRSA skin infection. 
Additionally, STZ provided more flexibility in using various transgenic mouse 
models to study the role of BLT1, macrophages, and use of fluorescent reporter 
mice that were not all available on the NOD background. Experiments using 
NOD mice were used to confirm some of the findings. 
  
Unbalanced inflammation driven by LTB4 
 High levels of LTB4 are detrimental for mycobacterial infections in a 
zebrafish model of infection [137, 139]. Additionally chronic inflammatory 
diseases are associated with higher levels of inflammatory cytokines and lipid 
mediators, including LTB4. Diabetic mice produce high levels of LTB4 in the 
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serum and inhibiting leukotriene production during sepsis in diabetic mice 
improves survival, which is also correlated with a reduction in inflammatory 
cytokines such as IL-1β [61]. However the role and contribution of IL-1β in the 
skin of diabetic mice is not yet understood. At day 1 post infection diabetic mice 
had slightly lower IL-1β than nondiabetic mice. Additionally, MyD88-blocking 
peptides had no effect on infection outcome in diabetic mice. Blocking MyD88 
would also inhibit signaling of other TLRs and IL-1β-family members, this 
suggests that other mediators are playing a predominate role in driving 
overwhelming inflammation in the skin of diabetic mice during MRSA skin 
infection. Future experiments are required to elucidate the role of these other 
mediators. 
  The location of LTB4 in the skin may contribute to poor host defense. 
Since LTB4 is a chemotactic molecule, excessive LTB4 levels may disrupt 
gradients in the skin, impairing neutrophil migration. Blocking BLT1 in diabetic 
mice restored neutrophil direction, possibly by altering expression or production 
of other chemotactic molecules or by allowing neutrophils to detect gradients of 
other chemokines in the skin. These events may allow for better abscess 
formation in diabetic mice during MRSA skin infection to improve bacterial 
containment.  
  
Macrophages in diabetic mice contribute to poor host defense 
 During MRSA skin infection, macrophages were found in close proximity 
to the neutrophilic abscess. In naive skin, there were no significant differences in 
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the levels of LTB4 produced, or the percentage of macrophages in the skin 
comparing diabetic and nondiabetic mice. During MRSA skin infection, high LTB4 
levels and dysregulated production of chemokines and cytokines was observed 
in diabetic mice. This suggests that MRSA skin infection uncontrolled cell 
activation. Since diabetic mice depleted of macrophages (DT-treated diabetic 
MMDTR mice) improved host defense, it is likely that macrophages in diabetic 
skin are promoting overwhelming inflammation. However, whether continuous 
macrophage depletion throughout the course of infection is beneficial remains to 
be determined. Since macrophages also have functions in eliminating apoptotic 
cells, it is likely that macrophage depletion at later stages of infection may 
interfere with the resolution phase.  
Others have reported that macrophages from db/db diabetic (type 2 
diabetes model) mice have impaired phagocytosis of apoptotic thymocytes [203] 
and that ob/ob (type 2 diabetes model) have impaired phagocytosis of apoptotic 
Jurkat T cells [204]. Although these are models of T2D, which were not 
investigated in these research goals, these studies support the hypothesis that 
uncontrolled apoptotic cell burden in the skin of diabetic mice during MRSA skin 
infection arise due to poor apoptotic cell clearance. Apoptotic cells that fail to be 
cleared can become necrotic and produce DAMPs, which are inflammatory 
signals [205]. There are many other receptors important for mediating or 
inhibiting efferocytosis. BAI1, TIM-4 and MerTK are receptors that recognize 
phosphatidylserine (PS). [206]. Our data suggest a role of SIRPα in mediating 
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poor efferocytosis in diabetic mice. However, more research is required to 
elucidate the roles for other receptors in apoptotic cell clearance.  
Additionally, the mechanism of cell death may contribute to the 
inflammatory milieu. Besides apoptosis, cell death mechanisms include 
necroptosis (programmed cell necrosis), autophagy, pyroptosis, and caspase-
independent cell death [207]. Distinguishing the mode of cell death is challenging 
[208]. Apoptotic cells can be labeled with TUNEL staining that detects DNA 
breaks. However, TUNEL staining does not differentiate between apoptosis and 
necrosis. Additionally, the presence of PS on the surface of cell membranes can 
be detected with AnnexinV labeling in combination with a cell impermeable DNA 
dye such as 7AAD. S. aureus has been reported to induce necrosis [156], 
necroptosis [209] and pyroptosis [210]. Although we observed high numbers of 
dead cells in the skin of diabetic mice during MRSA skin infection, future 
experiments are required to investigate the mechanism of cell death. 
 
Therapeutic potential of dampening LTB4/BLT1 actions 
 Overwhelming production of inflammatory mediators and reactive oxygen 
species are known to be detrimental to host defense in different models of 
infection [211-214]. Therapeutic strategies to block the actions of inflammatory 
mediators could also restore protective host defense mechanisms. It is known 
that people with diabetes are more susceptible to numerous infections, including 
systemic, respiratory, and skin infections [143, 145, 215]. Both innate and 
adaptive immune cells from diabetics have impaired functions including impaired 
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phagocytosis and killing of pathogens [147, 148]. Macrophages from diabetic 
mice produce higher levels of LTB4 than from control mice even under basal 
conditions [61]. Although seemingly counterintuitive, the mechanism by which 
people with diabetes are more susceptible to infections may operate in a similar 
manner to other infections where high levels of LTB4 are detrimental to host 
defense [61, 137, 139]. Since LTB4 is able to enhance IL-1β levels through 
inflammasome activation [120] and that LTB4/BLT1 signaling enhances MyD88 
and NFκB activities [60], it is possible that blocking LT synthesis or inhibiting 
BLT1 can prevent overwhelming inflammation.  
Diabetic mice are more susceptible to MRSA skin infection than 
nondiabetic mice. Diabetic mice infected with MRSA have increased LTB4 
production in the skin, which correlates with uncontrolled production of 
inflammatory mediators and neutrophil migration. Although LTB4 has therapeutic 
potential for better controlling MRSA skin infection, excessive LTB4/BLT1 actions 
could promote overwhelming inflammation. In the skin during MRSA skin 
infection, diabetic mice produce higher levels of LTB4 compared to nondiabetic 
mice. BLT1 antagonist treatment on diabetic mice dampened inflammation to 
limit neutrophil recruitment and cell death, restored neutrophil migration and 
abscess formation, which contributed to better bacterial control. 
 BLT1 antagonist treatment may be beneficial in various conditions in 
which chronic inflammation is detrimental. One example is with sepsis, which 
BLT1 antagonist treatment improved survival [141]. Another example is that 
BLT1 antagonist treatment prevented insulin resistance in a model of T2D [216]. 
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More research is needed to address how BLT1 antagonist treatment is beneficial 
and what the mechanisms of action are in various inflammatory conditions. 
The effects of BLT1 antagonist treatment on other cell types in the skin 
may play a role in reducing inflammation during infection. Keratinocytes express 
BLT1 and since the BLT1 antagonist treatment ointments are applied topically, 
the treatment may have effects on the keratinocytes. Keratinocytes produce 
cytokines and antimicrobial peptides [217]. Additionally, keratinocytes from 
people with diabetes have impaired cell migration and proliferation [218] and 
treating with the BLT1 antagonist may be altering the inflammatory profile of 
these cells, even in the absence of infection. More experiments are needed to 
determine how the BLT1 antagonist is altering the skin.  
 Although our data demonstrate that exaggerated LTB4 levels and 
uncontrolled BLT1 signaling are a driving factor for poor host defense in diabetic 
mice, we cannot exclude the possibility of other inflammatory mediators involved 
during MRSA skin infection. BLT1 antagonist treatment clearly improves host 
defense in diabetic mice, however the same treatment regime in nondiabetic 
mice exacerbate the infection. The mechanism by which the BLT1 antagonist 
demonstrates these seemingly counterintuitive effects is not well understood. It is 
possible that other inflammatory mediators are involved in host defense, which 
could be differentially produced between diabetic and nondiabetic mice. Future 
experiments are necessary to determine which cells in the skin are affected by 
BLT1 antagonism and the consequences of this treatment strategy.  
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numbers of dead cells were observed in diabetic mice. The levels of LTB4 
determine infection outcome. In nondiabetic mice, LTB4 is an important molecule 
in promoting antibacterial functions to eliminate MRSA. Additionally, combination 
ointment therapy of LTB4 and antibiotic mupirocin greatly accelerated the 
clearance of infection. Conversely, in settings of chronic inflammation such as 
diabetes, high LTB4 levels drove overwhelming inflammation and contributed to 
poor host defense. Dampening inflammation through blocking BLT1 improved 
host defense. Since the levels of LTB4 correlated with infection outcome, this 
highlights the importance of future research into investigating how underlying 
conditions affect inflammatory mediators. Therefore, targeting LTB4/BLT1 has 
therapeutic potential and has the potential for being applicable to other settings 
of vulnerability or chronic inflammation. For infections, this treatment strategy 
may be used in combination with antibiotics to better control infections.  
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FUTURE DIRECTIONS 
Part I – Beneficial LTB4 actions 
Role of skin-resident macrophages in MRSA skin infection 
 Due to the challenge of isolating sufficient macrophages from the skin for 
in vitro experimentation, it is difficult to study these cells. Also, the use of bone 
marrow derived macrophages or isolating macrophages from other locations, 
such as the peritoneum, may not serve as good models for dermal macrophages. 
Therefore, efforts into generating a skin macrophage cell line by transformation in 
order to retain more physiological characteristics rather than using macrophages 
isolated from another anatomical site. These cells will be used to investigate the 
role of skin-resident macrophages during MRSA skin infection. One strategy is to 
isolate F4/80+ cells from the skin of WT mice and infect the macrophages with J2 
retrovirus. J2 retrovirus carries the v-raf and v-myc oncogenes.  
 Once the cell line is established, the next step will be to characterize and 
compare gene expression profiles with AMJ2-C11 (alveolar macrophage cell line 
available at ATCC) and B6PMCL (C57BL/6 peritoneal macrophage cell line 
generated in our laboratory). Since these cells were generated with J2 retrovirus 
but are macrophages isolated from different areas (lung, peritoneal cavity, and 
skin), this will serve as comparisons. Cells will be stained with Diff-Quik for 
histological analysis. Single-cell RNA-seq will determine differences in gene 
expression and also to compare the dermal macrophages to primary dermal 
macrophages isolated from the skin of healthy mice. Functional analyses such as 
phagocytosis and cytokine and chemokine production will also be determined.  
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 If the dermal macrophage cell line shows a significantly different 
macrophage subset profile from the other cell lines, this would become a useful 
tool in the field to study the biology of skin-resident macrophages.  
 
Producers and responders of LTB4  
 LTB4 is an important molecule for controlling MRSA skin infections. 
Macrophage depletion resulted in lower LTB4 levels produced in the skin during 
MRSA skin infection suggesting that macrophages are a likely source for LTB4. 
However, macrophage depletion also significantly reduced neutrophil recruitment 
to the skin. Since neutrophils are also a source of LTB4 in the skin [81], it is 
possible that the reduction of LTB4 seen in macrophage-depleted mice is the 
result from fewer neutrophils recruited to the skin. Also, neutrophil depletion with 
Ly6G antibody treatment also reduced levels of LTB4, but not completely. It is 
likely that both macrophages and neutrophils are sources of LTB4. The goals for 
this future direction would be to identify which cells are producing LTB4 and which 
cells are responding to LTB4.  
 The use of MMDTR mice to deplete macrophages and Ly6G antibody to 
deplete neutrophils will help determine the role of these cells in LTB4 production. 
Depleting macrophages and neutrophils in the same animals would eliminate 
both cell types and would be expected to produce very little LTB4 in the skin. 
However, eliminating macrophages and neutrophils during infection brings up the 
concern that these cells have other functions (phagocytosis and killing of 
pathogens, and producing other chemokines) that would also be eliminated. 
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Therefore, generating a Alox5flox mouse with CRISPR/CAS9 would be a useful 
tool to knockout leukotriene production in various cell types by crossing them to 
various Cre-specific mouse strains: LysMcre would eliminate leukotriene 
production from myeloid cells, Csf1rcre from macrophages, MRP8cre from 
neutrophils, CD11ccre from dendritic cells, Adipoqcre from adipocytes, Krt17cre 
from keratinocytes, and Col1a2cre from fibroblasts. Eliminating 5-LO expression in 
various cell types would determine which cell types are important for leukotriene 
production during MRSA skin infection.  
Potential problems could be that eliminating 5-LO activity in various cell 
types may induce compensatory production of leukotrienes by other cells. 
Additionally, 5-LO deficiency impairs the production of all leukotrienes and other 
5-LO metabolites. The role of these other metabolites by individual cell may be 
overlooked with the proposed Alox5flox mouse model. However, another strategy 
to add back various leukotrienes in ointment form may be utilized to determine 
whether certain leukotrienes are involved in MRSA skin infection or not. 
Examples would be to treat Alox5 knockout or cell-specific knockout mice with 
topical ointments containing LTB4 or other leukotrienes such as LTD4, which has 
been shown to have antimicrobial defense activities [107].  
 Another future direction is to determine which cells are responding to 
LTB4. The use of the newly generated mouse model Ltb4r1LsL-DsRED-DTR would be 
a beneficial tool in studying BLT1 in various cell types during MRSA skin 
infection. These mice contain a floxed stop codon under the Ltb4r1 promoter, 
which is removed with cre recombination to generate DsRed-DTR expression. 
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The DsRED fluorescent marker will be useful to track the cells. Additionally, 
treating mice with diphtheria toxin will ablate these cells. The Ltb4r1LsL-DsRED-DTR 
mouse model will also be crossed with other Cre-expressing mouse strains: 
Csf1rcre for macrophages, MRP8cre for neutrophils, CD11ccre for dendritic cells, 
Adipoqcre for adipocytes, Krt17cre for keratinocytes, and Col1a2cre for fibroblasts. 
These mice will be used to study the role of BLT1 in various cell types during 
infection. The DTR allows for the specific deletion of these cells at various times 
before or during infection in order to evaluate the role of these cells are different 
stages of the infection.  
 
Abscess formation and resolution 
 There is great interest in studying the mediators that initiate abscess 
formation and which mediators regulate and end swarming. Microscale arrays 
have been developed to study swarming behavior of neutrophils in vitro [219]. 
This technology will be adapted to study the role of LTB4 and swarming in 
response to MRSA. These assays will also be imaged by live-cell imaging 
techniques in co-culture experiments with macrophages.  
 In vitro 3D abscesses similar to tumor spheroid-models [220] will 
supplement the 2D microscale arrays. Neutrophils, macrophages, and MRSA will 
be embedded in a matrix-gel (such as collagen) and cell migration will be 
observed. Live-cell imaging will be used with fluorescently labeled macrophages, 
neutrophils, and fibroblasts to visualize interactions between these cells. Co-
culture experiments with various cell types will help determine the roles and 
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contributions of these cells during MRSA infection. Also, since abscess formation 
is important for bacterial clearance, these experiments will help address the 
consequences of poor abscess formation. Additionally, some abscesses can 
become problematic and require surgical drainage. Experiments investigating the 
factors involved in abscess formation and resolution may help determine how 
abscesses become chronic.  
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Part II – Detrimental LTB4 actions 
Insulin versus hyperglycemia 
 Mice that were induced to be diabetic with STZ did not have significantly 
impaired host defense after 10 days (data not shown). However, mice that were 
diabetic for 30 days prior to MRSA skin infection displayed impaired host 
defense. Attempts to treat diabetic mice with insulin during the course of MRSA 
skin infection failed to improve host defense (data not shown). This may suggest 
that chronic diabetes irreversibly alters immune functions. One strategy will be to 
treat diabetic mice with insulin and maintain euglycemia for various lengths of 
time prior to MRSA skin infection. This would determine whether maintaining 
glucose levels reduce the susceptibility to infection risk. Another strategy is to 
treat mice with phlorizin to reduce blood glucose levels without altering insulin 
levels.  
 Also, investigating T2D models will also help elucidate the role of insulin 
vs. hyperglycemia. Diabetic NOD mice and STZ-induced diabetic mice, which 
both have low insulin levels and hyperglycemia, both have worse outcome to 
MRSA skin infection compared to their nondiabetic controls. T2D models db/db 
and control db/+ mice will be used to investigate whether type 2 diabetic mice 
also have worse MRSA skin infection and whether topical BLT1 antagonist would 
improve host defense. Type 2 diabetic mice will be treated with phlorizin to lower 
blood glucose levels prior to MRSA skin infection to determine whether the 
treatment improves host defense.  
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 The goals with this aim are to investigate the impact of insulin and 
hyperglycemia on host defense during MRSA skin infection and whether the 
mechanisms of poor host defense are driven by similar mechanisms between 
T1D and T2D. If there are differences between T1D and T2D, this may indicate 
that treatment recommendations may need to be tailored depending on 
underlying conditions.  
 
Balance of eicosanoids 
 Eicosanoids encompass a wide family of lipid mediators but all arise from 
arachidonic acid. From arachidonic acid, leukotrienes are produced from 
lipoxygenase activity and prostaglandins are produced from cyclooxygenase 
activity. 
  Diabetic mice have lower levels of PGE2 in the skin during MRSA skin 
infection compared to nondiabetic control mice [176]. Host defense was restored 
when diabetic mice were treated with a topical ointment containing misoprostol, a 
PGE analog. Complementary to this, diabetic mice have high LTB4 levels in the 
skin which drives poor host defense. In both instances, targeting the impairment 
restores host defense in diabetic mice. Whether host defense mechanisms are 
restored in similar mechanisms will be addressed. Low PGE2 levels in diabetic 
impaired dendritic cell maturation and migration to the lymph nodes, which 
impaired the recruitment of beneficial Th17 cells to the site of infection. Whether 
BLT1 antagonist treatment restores Th17 activation and IL-17 production will be 
determined. Additionally, BLT1 antagonist treatment in diabetic mice reduced 
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neutrophil recruitment and allowed for better abscess formation and bacterial 
clearance. It will be determined whether topical misoprostol treatment improves 
these events. Additionally, diabetic mice will be treated with topical ointments 
containing BLT1 antagonist and the PGE analog misoprostol to evaluate 
combination therapy. These therapies will further be evaluated in combination 
with antibiotic therapy. 
 Biopsy samples will be collected at various time points during infection 
and mass spectrometry analysis will be used to measure the levels of 
eicosanoids and whether BLT1 antagonist of PGE analog treatments restore the 
eicosanoid balance in the skin. In order to determine whether PGE2 or LTB4 is 
more dominant, diabetic mice treated with misoprostol will also be treated with 
topical LTB4 ointment, and diabetic mice treated with BLT1 antagonist will be 
treated with indomethacin or EP receptor antagonists. This will determine 
whether treating mice with the opposing treatment would inhibit the beneficial 
treatment.  
 Along with the balance of eicosanoids, the role of LTB4 on BLT1 and BLT2 
can be investigated in more detail. Whether BLT2 is involved during MRSA skin 
infections is not well understood. Although no significant effects were observed 
when diabetic mice were treated with BLT2 antagonist, the treatment dose and 
regime could be altered. Also, other cyclooxygenase products such as 12-HHT 
can signal through BLT2 and has been shown to improve wound healing in 
diabetic mice. Mice deficient in BLT1, BLT2, or both BLT1/2 will be studied. Also 
the use of U-75302 and LY255283 and LTB4 and BLT2 agonists will be used to 
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treat mice and in vitro cell cultures. It would be expected that if 12-HHT is 
necessary for wound healing, that BLT2 antagonist treatment may exacerbate 
the infection.  
 
Cell death pathways and mechanisms of clearance 
 Higher abundance of dead cells was observed in the skin of diabetic mice. 
The contribution of dead cell burden could result from one or a combination of 
the following: more neutrophil recruitment, signals in the skin triggering cell 
death, or inefficient efferocytosis to remove dead cells. TUNEL staining and flow 
cytometry analysis for 7AAD and AnnexinV show higher numbers of dead cells in 
skin of diabetic mice during infection. However, the majority of dead cells were 
not dying by caspase-3 activation for apoptosis (data not shown). The use of 
inhibitors or mice with genetic knockout for various proteins involved in the cell 
death pathways may reveal how the cells are dying in the skin.  
 How the cells die may alter the potential of the phagocytic cell to promote 
inflammation [221, 222]. Cells infected with S. aureus have been reported to die 
by various mechanisms [156, 209, 210]. Future experiments will help determine 
whether the cell death pathway is different in cells in the skin of diabetic mice, 
and whether BLT1 antagonist treatment alters this process. If there are 
differences in cell death mechanisms between diabetic and nondiabetic mice, 
future experiments will be performed to assess the activation and inflammatory 
profile of macrophages that engulf dead cells.  
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